EGFR-Mutant Non-Small Cell Lung Cancer

MONDO:0005061 Pathograph 4 non-small cell lung carcinoma

EGFR-mutant non-small cell lung cancer (NSCLC) is a molecularly-defined lung cancer subtype driven by activating mutations in the epidermal growth factor receptor (EGFR) gene. EGFR mutations occur in approximately 10-15% of NSCLC in Western populations and 40-50% in East Asian populations. Common mutations include exon 19 deletions and L858R point mutation (exon 21), which together account for ~85% of EGFR mutations and confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR-mutant NSCLC represents a paradigm for precision oncology in solid tumors, with multiple generations of targeted therapy and well-characterized resistance mechanisms.

Ask OpenScientist

Ask a research question about EGFR-Mutant Non-Small Cell Lung Cancer. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

Mappings

Definitions

Inheritance

Differentials

Datasets

Trials

Models

References

Deep Research

🏷

Classifications

Harrison's Chapter

ICD-O Morphology

◆

Subtypes

EGFR Exon 19 Deletion NSCLC

In-frame deletions in exon 19 (most commonly delE746-A750) account for approximately 45% of EGFR mutations. Generally associated with better response to TKIs and longer progression-free survival than L858R.

EGFR L858R Mutant NSCLC

Point mutation substituting arginine for leucine at codon 858 in exon 21. Accounts for approximately 40% of EGFR mutations. Sensitive to EGFR TKIs though potentially less so than exon 19 deletions.

EGFR Exon 20 Insertion NSCLC

In-frame insertions in exon 20 account for 5-10% of EGFR mutations. Most are resistant to first- through third-generation TKIs. Amivantamab and mobocertinib approved specifically for this population.

EGFR T790M Resistance NSCLC

T790M gatekeeper mutation emerges in ~50-60% of patients progressing on first/second-generation TKIs. Sensitive to third-generation TKI osimertinib.

⚙

Pathophysiology

EGFR Oncogenic Mutations

Activating EGFR mutations occur in the tyrosine kinase domain and cause constitutive receptor activation independent of ligand binding. Mutations alter the ATP-binding pocket, favoring the active kinase conformation and enhancing sensitivity to ATP-competitive TKIs.

type II pneumocyte link

epidermal growth factor receptor signaling pathway link ↑ INCREASED

Downstream

Constitutive EGFR Signaling Mutant receptors signal without ligand stimulation

Show evidence (1 reference)

PMID:15118073 SUPPORT Human Clinical

"Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P<0.001). Mutations were either small, in-frame deletions or amino acid substitutions..."

Lynch et al. 2004 landmark paper identifying somatic EGFR mutations in the tyrosine kinase domain that correlate with gefitinib sensitivity, establishing the molecular basis of EGFR-mutant NSCLC.

Constitutive EGFR Signaling

Mutant EGFR is constitutively phosphorylated, activating downstream signaling cascades including RAS-RAF-MEK-ERK (proliferation) and PI3K-AKT-mTOR (survival). The tumor becomes dependent on (addicted to) EGFR signaling for survival.

MAPK cascade link ↑ INCREASED phosphatidylinositol 3-kinase signaling link ↑ INCREASED

Downstream

Oncogene Addiction Tumor survival becomes dependent on EGFR pathway

Oncogene Addiction

EGFR-mutant tumors exhibit oncogene addiction, with survival critically dependent on continued EGFR signaling. EGFR inhibition leads to rapid tumor regression through induction of apoptosis and cell cycle arrest. This creates the therapeutic window for TKI therapy.

cell population proliferation link ↑ INCREASED

Downstream

TKI Resistance Mechanisms Selective pressure from EGFR-targeted therapy drives emergence of secondary mutations and bypass pathways.

Show evidence (1 reference)

PMID:29151359 SUPPORT Human Clinical

"Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events."

The FLAURA trial demonstrates the clinical manifestation of oncogene addiction in EGFR-mutant NSCLC, with high response rates to targeted EGFR inhibition.

TKI Resistance Mechanisms

Resistance to EGFR TKIs develops through multiple mechanisms: secondary EGFR mutations (T790M, C797S), bypass pathway activation (MET amplification, HER2 amplification and other oncogenic fusions), AP-1/EMT transcriptional states, and histologic transformation (small cell or squamous). Understanding resistance guides sequential therapy selection and combination strategies.

response to drug link ⚠ ABNORMAL

Show evidence (5 references)

PMID:15737014 SUPPORT Human Clinical

"in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain."

Pao et al. 2005 discovery of the T790M gatekeeper mutation as the molecular basis of acquired resistance to first-generation EGFR TKIs.

PMID:21430269 SUPPORT Human Clinical

"some acquired known mechanisms of resistance including the EGFR T790M mutation or MET gene amplification. Some resistant cancers showed unexpected genetic changes including EGFR amplification and mutations in the PIK3CA gene, whereas others underwent a pronounced epithelial-to-mesenchymal..."

Sequist et al. 2011 systematic analysis of 37 resistant tumors revealing the diversity of acquired resistance mechanisms including T790M, MET amplification, PIK3CA mutations, EMT, and SCLC transformation.

PMID:37060646 SUPPORT Other

"the C797S EGFR mutation"

Review summarizes C797S as a major EGFR-dependent resistance mechanism after osimertinib.

+ 2 more references

Immune-Cold Microenvironment

EGFR-mutant NSCLC often has limited benefit from immunotherapy compared with unselected NSCLC. High PD-L1 expression may define a more aggressive biological subgroup, but PD-1/PD-L1 blockade is generally sequenced after targeted and chemotherapy options rather than replacing EGFR-directed therapy.

Show evidence (1 reference)

PMID:41371099 SUPPORT Human Clinical

"Higher PD-L1 (≥25 %, ≥50 %, ≥75 % versus below each threshold) was associated with shorter rwPFS."

Real-world cohort and meta-analysis associate higher PD-L1 with shorter outcomes on first-line osimertinib.

✶

Histopathology

Adenocarcinoma Predominance VERY_FREQUENT

Adenocarcinoma is the most common histologic subtype in NSCLC.

Show evidence (1 reference)

PMID:32657049 PARTIAL

"Of 256 patients with NSCLC, 219 were adenocarcinoma"

Abstract reports a NSCLC cohort dominated by adenocarcinoma.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Metabolism 1

Pleural Effusion Pleural effusion (HP:0002202)

Respiratory 2

Cough Cough (HP:0012735)

Dyspnea Dyspnea (HP:0002094)

Growth 1

Weight Loss Weight loss (HP:0001824)

Neoplasm 4

Lung Adenocarcinoma VERY_FREQUENT Lung adenocarcinoma (HP:0030078)

Never/Light Smoker Association VERY_FREQUENT Neoplasm of the lung (HP:0100526)

Show evidence (1 reference)

PMID:27738317 SUPPORT Human Clinical

"The pooled prevalence of EGFR mutation was higher in females (females vs. males: 43.7% vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9), non-smokers (non-smokers vs. past or current smokers: 49.3% vs. 21.5%; OR: 3.7, 95% CI: 3.4 to 4.0), and patients with adenocarcinoma (adenocarcinoma vs...."

Large meta-analysis of 456 studies and 115,815 NSCLC patients showing non-smokers have 3.7-fold higher EGFR mutation prevalence than smokers.

Female and Asian Predominance FREQUENT Neoplasm of the lung (HP:0100526)

Show evidence (1 reference)

PMID:27738317 SUPPORT Human Clinical

"The overall pooled prevalence for EGFR mutations was 32.3% (95% CI 30.9% to 33.7%), ranging from 38.4% (95% CI: 36.5% to 40.3%) in China to 14.1% (95% CI: 12.7% to 15.5%) in Europe."

Meta-analysis confirming geographic variation in EGFR mutation prevalence, with substantially higher rates in Asian populations.

Brain Metastases FREQUENT Neoplasm of the nervous system (HP:0004375)

Show evidence (2 references)

PMID:25682925 SUPPORT Human Clinical

"BM were present in 24.4% of EGFR-mutated and 23.8% of ALK-rearranged NSCLCs at the time of diagnosis of advanced disease."

Rangachari et al. demonstrate that brain metastases are present in approximately one quarter of EGFR-mutant NSCLC patients at diagnosis.

PMID:25682925 SUPPORT Human Clinical

"BM are frequent in advanced EGFR-mutated or ALK-rearranged NSCLCs, with an estimated >45% of patients with CNS involvement by three years of survival with the use of targeted therapies."

The cumulative incidence of brain metastases increases substantially over time, reaching over 45% by 3 years of targeted therapy treatment.

🧬

Genetic Associations

EGFR (Somatic Activating Mutations)

Somatic

Show evidence (3 references)

PMID:15118073 SUPPORT Human Clinical

"A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib. These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor."

Lynch et al. 2004 identified somatic EGFR mutations as the molecular basis for TKI sensitivity, establishing the genetic foundation of this disease subtype.

PMID:26490356 PARTIAL

"Exon 19 deletion and exon 21 L858R mutation were the most common epidermal growth factor receptor (EGFR) mutations."

Supports the common EGFR mutation spectrum, but does not directly establish the broader activating/resistance mutation framework.

CIVIC_ASSERTION:105 SUPPORT Other

"Non-small cell lung cancer with EGFR L858R mutation is sensitive to gefitinib."

CIViC's accepted assertion supports EGFR L858R as a recurrent treatment-sensitive activating mutation in NSCLC.

💊

Treatments

Osimertinib

Action: pharmacotherapy MAXO:0000058

Agent: osimertinib ↗

Third-generation EGFR TKI that targets both sensitizing mutations and T790M resistance mutation while sparing wild-type EGFR. First-line standard of care for EGFR-mutant NSCLC based on FLAURA trial showing superior OS, with established roles in adjuvant resected disease and after definitive chemoradiotherapy for unresectable stage III disease. Excellent CNS penetration.

Show evidence (5 references)

PMID:31751012 SUPPORT Human Clinical

"Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI."

FLAURA trial final overall survival analysis demonstrating that first-line osimertinib provides a significant OS benefit (38.6 vs 31.8 months) over comparator EGFR-TKIs.

PMID:29151359 SUPPORT Human Clinical

FLAURA trial primary analysis confirming osimertinib superiority over first-generation EGFR TKIs for first-line treatment, with 18.9 vs 10.2 months median PFS.

PMID:42033967 SUPPORT Other

"adjuvant osimertinib now representing the most mature perioperative strategy"

Review supports adjuvant osimertinib as the most mature perioperative strategy for resectable EGFR-mutant NSCLC.

+ 2 more references

Erlotinib

Action: pharmacotherapy MAXO:0000058

Agent: erlotinib ↗

First-generation EGFR TKI. One of the original targeted therapies for EGFR-mutant NSCLC. Now largely replaced by osimertinib in first-line setting.

Show evidence (1 reference)

CIVIC_ASSERTION:5 SUPPORT Other

"Non-small cell lung cancer with EGFR L858R mutation is sensitive to erlotininib."

CIViC's accepted assertion directly supports erlotinib sensitivity in EGFR L858R-mutant NSCLC.

Afatinib

Action: pharmacotherapy MAXO:0000058

Agent: afatinib ↗

Second-generation irreversible EGFR-family TKI used for sensitizing EGFR mutations including L858R. It is part of the EGFR TKI treatment class now commonly sequenced around osimertinib.

Show evidence (1 reference)

CIVIC_ASSERTION:6 SUPPORT Other

"EGFR L858R positive NSCLC is sensitive to afatinib."

CIViC's accepted assertion directly supports afatinib sensitivity in EGFR L858R-mutant NSCLC.

Gefitinib

Action: pharmacotherapy MAXO:0000058

Agent: gefitinib ↗

First-generation EGFR TKI approved for EGFR-mutant NSCLC. The IPASS trial established gefitinib as superior to chemotherapy in EGFR mutation-positive patients. Largely supplanted by osimertinib.

Show evidence (2 references)

PMID:21670455 SUPPORT Human Clinical

"EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel."

IPASS final analysis confirmed EGFR mutation status as the key predictive biomarker for first-line gefitinib, establishing the molecular selection paradigm for EGFR TKI therapy.

CIVIC_ASSERTION:105 SUPPORT Other

"Non-small cell lung cancer with EGFR L858R mutation is sensitive to gefitinib."

CIViC's accepted assertion directly supports gefitinib sensitivity in EGFR L858R-mutant NSCLC.

Amivantamab

Action: pharmacotherapy MAXO:0000058

Agent: amivantamab ↗

Bispecific antibody targeting EGFR and MET. Approved for EGFR exon 20 insertion mutations, which are resistant to most classic TKIs, including in combination with chemotherapy as first-line therapy for advanced Ex20ins-mutated NSCLC.

Show evidence (2 references)

PMID:41671629 SUPPORT Human Clinical

"PAPILLON trial (NCT04538664) demonstrated that amivantamab plus chemotherapy"

PAPILLON supports amivantamab plus chemotherapy as first-line treatment for advanced EGFR exon 20 insertion-mutated NSCLC.

PMID:41671629 SUPPORT Human Clinical

"Amivantamab plus chemotherapy significantly delays symptomatic"

Patient-reported outcome analysis supports symptomatic progression benefit without compromising quality of life.

Chemotherapy

Action: chemotherapy MAXO:0000647

Platinum-based chemotherapy (carboplatin/pemetrexed) used at progression on targeted therapy, including after third-generation EGFR TKI resistance with C797S. May be combined with EGFR-directed agents in selected settings.

Show evidence (1 reference)

PMID:41430586 SUPPORT Human Clinical

"chemotherapy-based treatments remain the standard of care"

Real-world C797S analysis supports chemotherapy-based treatment after third-generation EGFR TKI resistance.

🔬

Biochemical Markers

EGFR Mutation Testing

{ }

Source YAML

click to show

name: EGFR-Mutant Non-Small Cell Lung Cancer
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-05-11T02:45:15Z'
description: >-
  EGFR-mutant non-small cell lung cancer (NSCLC) is a molecularly-defined lung
  cancer subtype driven by activating mutations in the epidermal growth factor
  receptor (EGFR) gene. EGFR mutations occur in approximately 10-15% of NSCLC
  in Western populations and 40-50% in East Asian populations. Common mutations
  include exon 19 deletions and L858R point mutation (exon 21), which together
  account for ~85% of EGFR mutations and confer sensitivity to EGFR tyrosine
  kinase inhibitors (TKIs). EGFR-mutant NSCLC represents a paradigm for precision
  oncology in solid tumors, with multiple generations of targeted therapy and
  well-characterized resistance mechanisms.
categories:
- Molecularly-Defined Cancer
- Lung Cancer Subtype
- Solid Tumor
parents:
- non-small cell lung carcinoma
external_assertions:
- name: CIViC EGFR L858R erlotinib sensitivity assertion
  source: CIViC
  assertion_type: accepted_assertion
  external_id: CIVIC_ASSERTION:5
  url: https://civicdb.org/links/assertions/5
  description: >-
    CIViC accepted assertion that EGFR L858R in non-small cell lung cancer
    predicts sensitivity/response to erlotinib.
  notes: >-
    01-May-2026 CIViC accepted assertion: molecular_profile="EGFR L858R";
    disease="Lung Non-small Cell Carcinoma"; assertion_type=Predictive;
    significance=Sensitivity/Response; therapy=Erlotinib; AMP category=Tier I - Level A.
  evidence:
  - reference: CIVIC_ASSERTION:5
    reference_title: "EGFR L858R / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Non-small cell lung cancer with EGFR L858R mutation is sensitive to erlotininib.
    explanation: CIViC records an accepted predictive sensitivity assertion for EGFR L858R and erlotinib in NSCLC.
- name: CIViC EGFR L858R afatinib sensitivity assertion
  source: CIViC
  assertion_type: accepted_assertion
  external_id: CIVIC_ASSERTION:6
  url: https://civicdb.org/links/assertions/6
  description: >-
    CIViC accepted assertion that EGFR L858R in non-small cell lung cancer
    predicts sensitivity/response to afatinib.
  notes: >-
    01-May-2026 CIViC accepted assertion: molecular_profile="EGFR L858R";
    disease="Lung Non-small Cell Carcinoma"; assertion_type=Predictive;
    significance=Sensitivity/Response; therapy=Afatinib; AMP category=Tier I - Level A.
  evidence:
  - reference: CIVIC_ASSERTION:6
    reference_title: "EGFR L858R / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: EGFR L858R positive NSCLC is sensitive to afatinib.
    explanation: CIViC records an accepted predictive sensitivity assertion for EGFR L858R and afatinib in NSCLC.
- name: CIViC EGFR L858R gefitinib sensitivity assertion
  source: CIViC
  assertion_type: accepted_assertion
  external_id: CIVIC_ASSERTION:105
  url: https://civicdb.org/links/assertions/105
  description: >-
    CIViC accepted assertion that EGFR L858R in non-small cell lung cancer
    predicts sensitivity/response to gefitinib.
  notes: >-
    01-May-2026 CIViC accepted assertion: molecular_profile="EGFR L858R";
    disease="Lung Non-small Cell Carcinoma"; assertion_type=Predictive;
    significance=Sensitivity/Response; therapy=Gefitinib; AMP category=Tier I - Level A.
  evidence:
  - reference: CIVIC_ASSERTION:105
    reference_title: "EGFR L858R / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Non-small cell lung cancer with EGFR L858R mutation is sensitive to gefitinib.
    explanation: CIViC records an accepted predictive sensitivity assertion for EGFR L858R and gefitinib in NSCLC.
- name: CIViC EGFR T790M osimertinib sensitivity assertion
  source: CIViC
  assertion_type: accepted_assertion
  external_id: CIVIC_ASSERTION:130
  url: https://civicdb.org/links/assertions/130
  description: >-
    CIViC accepted assertion that EGFR T790M in non-small cell lung cancer
    predicts sensitivity/response to osimertinib.
  notes: >-
    01-May-2026 CIViC accepted assertion: molecular_profile="EGFR T790M";
    disease="Lung Non-small Cell Carcinoma"; assertion_type=Predictive;
    significance=Sensitivity/Response; therapy=Osimertinib; AMP category=Tier I - Level A.
  evidence:
  - reference: CIVIC_ASSERTION:130
    reference_title: "EGFR T790M / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: EGFR T790M predicts sensitivity to osimertinib in non-small cell lung cancer
    explanation: CIViC records an accepted predictive sensitivity assertion for EGFR T790M and osimertinib in NSCLC.
has_subtypes:
- name: EGFR Exon 19 Deletion NSCLC
  description: >-
    In-frame deletions in exon 19 (most commonly delE746-A750) account for
    approximately 45% of EGFR mutations. Generally associated with better
    response to TKIs and longer progression-free survival than L858R.
- name: EGFR L858R Mutant NSCLC
  description: >-
    Point mutation substituting arginine for leucine at codon 858 in exon 21.
    Accounts for approximately 40% of EGFR mutations. Sensitive to EGFR TKIs
    though potentially less so than exon 19 deletions.
- name: EGFR Exon 20 Insertion NSCLC
  description: >-
    In-frame insertions in exon 20 account for 5-10% of EGFR mutations. Most
    are resistant to first- through third-generation TKIs. Amivantamab and
    mobocertinib approved specifically for this population.
- name: EGFR T790M Resistance NSCLC
  description: >-
    T790M gatekeeper mutation emerges in ~50-60% of patients progressing on
    first/second-generation TKIs. Sensitive to third-generation TKI osimertinib.
pathophysiology:
- name: EGFR Oncogenic Mutations
  description: >-
    Activating EGFR mutations occur in the tyrosine kinase domain and cause
    constitutive receptor activation independent of ligand binding. Mutations
    alter the ATP-binding pocket, favoring the active kinase conformation
    and enhancing sensitivity to ATP-competitive TKIs.
  evidence:
  - reference: PMID:15118073
    reference_title: "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P<0.001). Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain."
    explanation: >-
      Lynch et al. 2004 landmark paper identifying somatic EGFR mutations in the
      tyrosine kinase domain that correlate with gefitinib sensitivity, establishing
      the molecular basis of EGFR-mutant NSCLC.
  cell_types:
  - preferred_term: type II pneumocyte
    term:
      id: CL:0002063
      label: pulmonary alveolar type 2 cell
  biological_processes:
  - preferred_term: epidermal growth factor receptor signaling pathway
    modifier: INCREASED
    term:
      id: GO:0007173
      label: epidermal growth factor receptor signaling pathway
  downstream:
  - target: Constitutive EGFR Signaling
    description: Mutant receptors signal without ligand stimulation
- name: Constitutive EGFR Signaling
  description: >-
    Mutant EGFR is constitutively phosphorylated, activating downstream signaling
    cascades including RAS-RAF-MEK-ERK (proliferation) and PI3K-AKT-mTOR
    (survival). The tumor becomes dependent on (addicted to) EGFR signaling
    for survival.
  biological_processes:
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
  - preferred_term: phosphatidylinositol 3-kinase signaling
    modifier: INCREASED
    term:
      id: GO:0043491
      label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
  downstream:
  - target: Oncogene Addiction
    description: Tumor survival becomes dependent on EGFR pathway
- name: Oncogene Addiction
  description: >-
    EGFR-mutant tumors exhibit oncogene addiction, with survival critically
    dependent on continued EGFR signaling. EGFR inhibition leads to rapid
    tumor regression through induction of apoptosis and cell cycle arrest.
    This creates the therapeutic window for TKI therapy.
  evidence:
  - reference: PMID:29151359
    reference_title: "Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events."
    explanation: >-
      The FLAURA trial demonstrates the clinical manifestation of oncogene addiction
      in EGFR-mutant NSCLC, with high response rates to targeted EGFR inhibition.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  downstream:
  - target: TKI Resistance Mechanisms
    description: Selective pressure from EGFR-targeted therapy drives emergence of secondary mutations and bypass pathways.
- name: TKI Resistance Mechanisms
  description: >-
    Resistance to EGFR TKIs develops through multiple mechanisms: secondary
    EGFR mutations (T790M, C797S), bypass pathway activation (MET amplification,
    HER2 amplification and other oncogenic fusions), AP-1/EMT transcriptional
    states, and histologic transformation (small cell or squamous). Understanding
    resistance guides sequential therapy selection and combination strategies.
  evidence:
  - reference: PMID:15737014
    reference_title: "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain."
    explanation: >-
      Pao et al. 2005 discovery of the T790M gatekeeper mutation as the
      molecular basis of acquired resistance to first-generation EGFR TKIs.
  - reference: PMID:21430269
    reference_title: "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "some acquired known mechanisms of resistance including the EGFR T790M mutation or MET gene amplification. Some resistant cancers showed unexpected genetic changes including EGFR amplification and mutations in the PIK3CA gene, whereas others underwent a pronounced epithelial-to-mesenchymal transition. Surprisingly, five resistant tumors (14%) transformed from NSCLC into small cell lung cancer (SCLC)"
    explanation: >-
      Sequist et al. 2011 systematic analysis of 37 resistant tumors revealing
      the diversity of acquired resistance mechanisms including T790M, MET
      amplification, PIK3CA mutations, EMT, and SCLC transformation.
  - reference: PMID:37060646
    reference_title: "Acquired resistance mechanisms to osimertinib: The constant battle."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: the C797S EGFR mutation
    explanation: Review summarizes C797S as a major EGFR-dependent resistance mechanism after osimertinib.
  - reference: PMID:40414926
    reference_title: Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: pharmacological inhibition of AP-1 reinstates
    explanation: Functional multi-omics supports AP-1-linked EMT and survival signaling as a targetable osimertinib resistance state.
  - reference: PMID:41927036
    reference_title: Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: MET amplification is one of the major
    explanation: Supports MET amplification as a bypass resistance mechanism and rationale for EGFR/MET combination strategies.
  biological_processes:
  - preferred_term: response to drug
    modifier: ABNORMAL
    term:
      id: GO:0009410
      label: response to xenobiotic stimulus
- name: Immune-Cold Microenvironment
  description: >-
    EGFR-mutant NSCLC often has limited benefit from immunotherapy compared with
    unselected NSCLC. High PD-L1 expression may define a more aggressive
    biological subgroup, but PD-1/PD-L1 blockade is generally sequenced after
    targeted and chemotherapy options rather than replacing EGFR-directed therapy.
  evidence:
  - reference: PMID:41371099
    reference_title: "Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Higher PD-L1 (≥25 %, ≥50 %, ≥75 % versus below each threshold) was associated with shorter rwPFS."
    explanation: Real-world cohort and meta-analysis associate higher PD-L1 with shorter outcomes on first-line osimertinib.
histopathology:
- name: Adenocarcinoma Predominance
  finding_term:
    preferred_term: Lung Adenocarcinoma
    term:
      id: NCIT:C3512
      label: Lung Adenocarcinoma
  frequency: VERY_FREQUENT
  description: Adenocarcinoma is the most common histologic subtype in NSCLC.
  evidence:
  - reference: PMID:32657049
    reference_title: "Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua."
    supports: PARTIAL
    snippet: "Of 256 patients with NSCLC, 219 were adenocarcinoma"
    explanation: Abstract reports a NSCLC cohort dominated by adenocarcinoma.

phenotypes:
- category: Neoplastic
  name: Lung Adenocarcinoma
  frequency: VERY_FREQUENT
  description: >-
    EGFR-mutant NSCLC is predominantly adenocarcinoma histology. Often presents
    as peripheral lung nodules with ground-glass or lepidic growth patterns.
  phenotype_term:
    preferred_term: Lung adenocarcinoma
    term:
      id: HP:0030078
      label: Lung adenocarcinoma
- category: Clinical
  name: Never/Light Smoker Association
  frequency: VERY_FREQUENT
  description: >-
    EGFR mutations are strongly associated with never-smoking or light smoking
    history. The prevalence of EGFR mutations is approximately 49% in
    non-smokers compared to 22% in past or current smokers.
  phenotype_term:
    preferred_term: Neoplasm of the lung
    term:
      id: HP:0100526
      label: Neoplasm of the lung
  evidence:
  - reference: PMID:27738317
    reference_title: "The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pooled prevalence of EGFR mutation was higher in females (females vs. males: 43.7% vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9), non-smokers (non-smokers vs. past or current smokers: 49.3% vs. 21.5%; OR: 3.7, 95% CI: 3.4 to 4.0), and patients with adenocarcinoma (adenocarcinoma vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 4.1, 95% CI: 3.6 to 4.8)."
    explanation: >-
      Large meta-analysis of 456 studies and 115,815 NSCLC patients showing
      non-smokers have 3.7-fold higher EGFR mutation prevalence than smokers.
- category: Demographic
  name: Female and Asian Predominance
  frequency: FREQUENT
  description: >-
    EGFR mutations are more common in females and individuals of East Asian
    ancestry. The pooled prevalence is 38.4% in China vs 14.1% in Europe,
    and 43.7% in females vs 24.0% in males.
  phenotype_term:
    preferred_term: Neoplasm of the lung
    term:
      id: HP:0100526
      label: Neoplasm of the lung
  evidence:
  - reference: PMID:27738317
    reference_title: "The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The overall pooled prevalence for EGFR mutations was 32.3% (95% CI 30.9% to 33.7%), ranging from 38.4% (95% CI: 36.5% to 40.3%) in China to 14.1% (95% CI: 12.7% to 15.5%) in Europe."
    explanation: >-
      Meta-analysis confirming geographic variation in EGFR mutation prevalence,
      with substantially higher rates in Asian populations.
- category: Clinical
  name: Brain Metastases
  frequency: FREQUENT
  description: >-
    Brain metastases occur in approximately 25% of EGFR-mutant NSCLC patients
    at diagnosis and increase to over 45% by three years. CNS-penetrant TKIs
    (osimertinib) have improved CNS disease control.
  phenotype_term:
    preferred_term: Neoplasm of the nervous system
    term:
      id: HP:0004375
      label: Neoplasm of the nervous system
  evidence:
  - reference: PMID:25682925
    reference_title: "Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BM were present in 24.4% of EGFR-mutated and 23.8% of ALK-rearranged NSCLCs at the time of diagnosis of advanced disease."
    explanation: >-
      Rangachari et al. demonstrate that brain metastases are present in
      approximately one quarter of EGFR-mutant NSCLC patients at diagnosis.
  - reference: PMID:25682925
    reference_title: "Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BM are frequent in advanced EGFR-mutated or ALK-rearranged NSCLCs, with an estimated >45% of patients with CNS involvement by three years of survival with the use of targeted therapies."
    explanation: >-
      The cumulative incidence of brain metastases increases substantially over
      time, reaching over 45% by 3 years of targeted therapy treatment.
- category: Clinical
  name: Cough
  description: >-
    Chronic cough is a common presenting symptom in EGFR-mutant NSCLC, often
    related to the primary lung mass or associated pleural effusion.
  phenotype_term:
    preferred_term: Cough
    term:
      id: HP:0012735
      label: Cough
- category: Clinical
  name: Dyspnea
  description: >-
    Breathlessness occurs commonly in EGFR-mutant NSCLC due to the primary
    tumor, pleural effusion, or metastatic disease burden.
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
- category: Clinical
  name: Pleural Effusion
  description: >-
    Malignant pleural effusion is common in EGFR-mutant NSCLC and may be a
    presenting feature. EGFR TKI treatment can resolve effusions in responsive
    patients.
  phenotype_term:
    preferred_term: Pleural effusion
    term:
      id: HP:0002202
      label: Pleural effusion
- category: Clinical
  name: Weight Loss
  description: >-
    Unintentional weight loss is a common systemic symptom in advanced
    EGFR-mutant NSCLC.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
biochemical:
- name: EGFR Mutation Testing
  notes: >-
    EGFR mutation testing is required for all advanced non-squamous NSCLC.
    Methods include PCR-based assays, next-generation sequencing, and ctDNA
    (liquid biopsy). Testing should detect common sensitizing mutations
    (exon 19 del, L858R), resistance mutations (T790M), and exon 20 insertions.
genetic:
- name: EGFR
  association: Somatic Activating Mutations
  inheritance:
  - name: Somatic
  notes: >-
    EGFR (7p11.2) encodes the epidermal growth factor receptor. Activating mutations
    occur somatically in the tyrosine kinase domain (exons 18-21). Exon 19
    deletions and L858R are classical sensitizing mutations. T790M (exon 20)
    and C797S (exon 20) are acquired resistance mutations. Exon 20 insertions
    are primary resistance mutations.
  evidence:
  - reference: PMID:15118073
    reference_title: "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib. These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor."
    explanation: >-
      Lynch et al. 2004 identified somatic EGFR mutations as the molecular
      basis for TKI sensitivity, establishing the genetic foundation of this
      disease subtype.
  - reference: PMID:26490356
    reference_title: "Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis."
    supports: PARTIAL
    snippet: "Exon 19 deletion and exon 21 L858R mutation were the most common epidermal growth factor receptor (EGFR) mutations."
    explanation: "Supports the common EGFR mutation spectrum, but does not directly establish the broader activating/resistance mutation framework."
  - reference: CIVIC_ASSERTION:105
    reference_title: "EGFR L858R / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Non-small cell lung cancer with EGFR L858R mutation is sensitive to gefitinib.
    explanation: CIViC's accepted assertion supports EGFR L858R as a recurrent treatment-sensitive activating mutation in NSCLC.
treatments:
- name: Osimertinib
  description: >-
    Third-generation EGFR TKI that targets both sensitizing mutations and T790M
    resistance mutation while sparing wild-type EGFR. First-line standard of care
    for EGFR-mutant NSCLC based on FLAURA trial showing superior OS, with
    established roles in adjuvant resected disease and after definitive
    chemoradiotherapy for unresectable stage III disease. Excellent CNS
    penetration.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: osimertinib
      term:
        id: CHEBI:90943
        label: osimertinib
  evidence:
  - reference: PMID:31751012
    reference_title: "Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI."
    explanation: >-
      FLAURA trial final overall survival analysis demonstrating that first-line
      osimertinib provides a significant OS benefit (38.6 vs 31.8 months) over
      comparator EGFR-TKIs.
  - reference: PMID:29151359
    reference_title: "Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events."
    explanation: >-
      FLAURA trial primary analysis confirming osimertinib superiority over
      first-generation EGFR TKIs for first-line treatment, with 18.9 vs 10.2
      months median PFS.
  - reference: PMID:42033967
    reference_title: "Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: adjuvant osimertinib now representing the most mature perioperative strategy
    explanation: Review supports adjuvant osimertinib as the most mature perioperative strategy for resectable EGFR-mutant NSCLC.
  - reference: PMID:41785639
    reference_title: "Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Osimertinib after definitive CRT demonstrated PFS benefit over
    explanation: LAURA China cohort supports consolidation osimertinib after definitive chemoradiotherapy in unresectable stage III EGFR-mutated NSCLC.
  - reference: CIVIC_ASSERTION:130
    reference_title: "EGFR T790M / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: EGFR T790M predicts sensitivity to osimertinib in non-small cell lung cancer
    explanation: CIViC's accepted assertion supports osimertinib sensitivity in EGFR T790M-positive NSCLC.
- name: Erlotinib
  description: >-
    First-generation EGFR TKI. One of the original targeted therapies for
    EGFR-mutant NSCLC. Now largely replaced by osimertinib in first-line setting.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: erlotinib
      term:
        id: CHEBI:114785
        label: erlotinib
  evidence:
  - reference: CIVIC_ASSERTION:5
    reference_title: "EGFR L858R / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Non-small cell lung cancer with EGFR L858R mutation is sensitive to erlotininib.
    explanation: CIViC's accepted assertion directly supports erlotinib sensitivity in EGFR L858R-mutant NSCLC.
- name: Afatinib
  description: >-
    Second-generation irreversible EGFR-family TKI used for sensitizing EGFR
    mutations including L858R. It is part of the EGFR TKI treatment class now
    commonly sequenced around osimertinib.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: afatinib
      term:
        id: CHEBI:61390
        label: afatinib
  evidence:
  - reference: CIVIC_ASSERTION:6
    reference_title: "EGFR L858R / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: EGFR L858R positive NSCLC is sensitive to afatinib.
    explanation: CIViC's accepted assertion directly supports afatinib sensitivity in EGFR L858R-mutant NSCLC.
- name: Gefitinib
  description: >-
    First-generation EGFR TKI approved for EGFR-mutant NSCLC. The IPASS trial
    established gefitinib as superior to chemotherapy in EGFR mutation-positive
    patients. Largely supplanted by osimertinib.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: gefitinib
      term:
        id: CHEBI:49668
        label: gefitinib
  evidence:
  - reference: PMID:21670455
    reference_title: "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel."
    explanation: >-
      IPASS final analysis confirmed EGFR mutation status as the key predictive
      biomarker for first-line gefitinib, establishing the molecular selection
      paradigm for EGFR TKI therapy.
  - reference: CIVIC_ASSERTION:105
    reference_title: "EGFR L858R / Lung Non-small Cell Carcinoma (Predictive Sensitivity/Response)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Non-small cell lung cancer with EGFR L858R mutation is sensitive to gefitinib.
    explanation: CIViC's accepted assertion directly supports gefitinib sensitivity in EGFR L858R-mutant NSCLC.
- name: Amivantamab
  description: >-
    Bispecific antibody targeting EGFR and MET. Approved for EGFR exon 20
    insertion mutations, which are resistant to most classic TKIs, including in
    combination with chemotherapy as first-line therapy for advanced
    Ex20ins-mutated NSCLC.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: amivantamab
      term:
        id: NCIT:C124993
        label: Amivantamab
  evidence:
  - reference: PMID:41671629
    reference_title: "Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: PAPILLON trial (NCT04538664) demonstrated that amivantamab plus chemotherapy
    explanation: PAPILLON supports amivantamab plus chemotherapy as first-line treatment for advanced EGFR exon 20 insertion-mutated NSCLC.
  - reference: PMID:41671629
    reference_title: "Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Amivantamab plus chemotherapy significantly delays symptomatic
    explanation: Patient-reported outcome analysis supports symptomatic progression benefit without compromising quality of life.
- name: Chemotherapy
  description: >-
    Platinum-based chemotherapy (carboplatin/pemetrexed) used at progression
    on targeted therapy, including after third-generation EGFR TKI resistance
    with C797S. May be combined with EGFR-directed agents in selected settings.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
  evidence:
  - reference: PMID:41430586
    reference_title: Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: chemotherapy-based treatments remain the standard of care
    explanation: Real-world C797S analysis supports chemotherapy-based treatment after third-generation EGFR TKI resistance.
disease_term:
  preferred_term: lung adenocarcinoma
  term:
    id: MONDO:0005061
    label: lung adenocarcinoma

classifications:
  icdo_morphology:
    classification_value: Carcinoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
references:
- reference: DOI:10.1016/j.jncc.2024.06.004
  title: 'Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: 'Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review'
    supporting_text: 'Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review'
- reference: DOI:10.1016/j.pccm.2024.08.002
  title: Overcoming EGFR-TKI resistance by targeting the tumor microenvironment
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: Overcoming EGFR-TKI resistance by targeting the tumor microenvironment
    supporting_text: Overcoming EGFR-TKI resistance by targeting the tumor microenvironment
- reference: DOI:10.1038/s41417-024-00761-z
  title: 'Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell lung cancer (NSCLC) constitutes around 85% of all lung cancer cases.
    supporting_text: Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell lung cancer (NSCLC) constitutes around 85% of all lung cancer cases.
    evidence:
    - reference: DOI:10.1038/s41417-024-00761-z
      reference_title: 'Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell lung cancer (NSCLC) constitutes around 85% of all lung cancer cases.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: DOI:10.1038/s41418-024-01317-2
  title: 'PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: 'PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy'
    supporting_text: 'PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy'
- reference: DOI:10.1038/s41419-024-06945-7
  title: PD-L1 induces autophagy and primary resistance to EGFR–TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: Resistance to epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) is a significant cause of treatment failure and cancer recurrence in non-small cell lung cancer (NSCLC).
    supporting_text: Resistance to epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) is a significant cause of treatment failure and cancer recurrence in non-small cell lung cancer (NSCLC).
    evidence:
    - reference: DOI:10.1038/s41419-024-06945-7
      reference_title: PD-L1 induces autophagy and primary resistance to EGFR–TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Resistance to epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) is a significant cause of treatment failure and cancer recurrence in non-small cell lung cancer (NSCLC).
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: DOI:10.1080/14728222.2023.2218613
  title: 'Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: 'Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?'
    supporting_text: 'Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?'
- reference: DOI:10.1186/s12943-023-01780-4
  title: Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: RNA 5-methylcytosine (m5C) modification plays critical roles in the pathogenesis of various tumors.
    supporting_text: RNA 5-methylcytosine (m5C) modification plays critical roles in the pathogenesis of various tumors.
    evidence:
    - reference: DOI:10.1186/s12943-023-01780-4
      reference_title: Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: RNA 5-methylcytosine (m5C) modification plays critical roles in the pathogenesis of various tumors.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: DOI:10.21037/tlcr-23-98
  title: 'EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: 'EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates'
    supporting_text: 'EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates'
- reference: DOI:10.32604/or.2025.059311
  title: Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies
    supporting_text: Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies
- reference: DOI:10.3390/biomedicines13020470
  title: 'Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: Tyrosine kinase inhibitors (TKIs) have transformed the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer.
    supporting_text: Tyrosine kinase inhibitors (TKIs) have transformed the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer.
    evidence:
    - reference: DOI:10.3390/biomedicines13020470
      reference_title: 'Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Tyrosine kinase inhibitors (TKIs) have transformed the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: DOI:10.3390/ijms25115917
  title: Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: Non-small-cell lung cancer (NSCLC) frequently harbors mutations in the epidermal growth factor receptor (EGFR), with exon 20 insertions comprising 1–10% of these mutations.
    supporting_text: Non-small-cell lung cancer (NSCLC) frequently harbors mutations in the epidermal growth factor receptor (EGFR), with exon 20 insertions comprising 1–10% of these mutations.
    evidence:
    - reference: DOI:10.3390/ijms25115917
      reference_title: Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Non-small-cell lung cancer (NSCLC) frequently harbors mutations in the epidermal growth factor receptor (EGFR), with exon 20 insertions comprising 1–10% of these mutations.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: DOI:10.3390/ijms26072957
  title: Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: Non-small-cell lung cancer (NSCLC) represents the most common type of lung cancer.
    supporting_text: Non-small-cell lung cancer (NSCLC) represents the most common type of lung cancer.
    evidence:
    - reference: DOI:10.3390/ijms26072957
      reference_title: Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Non-small-cell lung cancer (NSCLC) represents the most common type of lung cancer.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: DOI:10.3892/ol.2025.15121
  title: 'EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: 'EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)'
    supporting_text: 'EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)'
- reference: DOI:10.62347/wtmu5537
  title: New advances in the treatment of EGFR exon20ins mutant advanced NSCLC
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-cyberian-codex.md
  - EGFR_Mutant_NSCLC-deep-research-falcon.md
  findings:
  - statement: New advances in the treatment of EGFR exon20ins mutant advanced NSCLC
    supporting_text: New advances in the treatment of EGFR exon20ins mutant advanced NSCLC
- reference: PMID:16989002
  title: Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Chemonaive patients had higher response rates than chemotherapy-treated patients in previous analyses of East Asian patients with advanced nonsmall cell lung cancer.
    supporting_text: Chemonaive patients had higher response rates than chemotherapy-treated patients in previous analyses of East Asian patients with advanced nonsmall cell lung cancer.
    evidence:
    - reference: PMID:16989002
      reference_title: Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Chemonaive patients had higher response rates than chemotherapy-treated patients in previous analyses of East Asian patients with advanced nonsmall cell lung cancer.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:21527061
  title: 'East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2011 May;30(5):287-92. doi: 10.5732/cjc.011.10106.'
    supporting_text: '2011 May;30(5):287-92. doi: 10.5732/cjc.011.10106.'
    evidence:
    - reference: PMID:21527061
      reference_title: 'East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2011 May;30(5):287-92. doi: 10.5732/cjc.011.10106.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:23299280
  title: Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Worldwide studies on lung adenocarcinoma have demonstrated a genetic divergence of the epidermal growth factor receptor (EGFR) pathway according to ethnicity, such as higher frequency of activated EGFR mutations among East Asian patients.
    supporting_text: Worldwide studies on lung adenocarcinoma have demonstrated a genetic divergence of the epidermal growth factor receptor (EGFR) pathway according to ethnicity, such as higher frequency of activated EGFR mutations among East Asian patients.
    evidence:
    - reference: PMID:23299280
      reference_title: Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Worldwide studies on lung adenocarcinoma have demonstrated a genetic divergence of the epidermal growth factor receptor (EGFR) pathway according to ethnicity, such as higher frequency of activated EGFR mutations among East Asian patients.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:27501781
  title: Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2016 Aug 9;7:12451. doi: 10.1038/ncomms12451.'
    supporting_text: '2016 Aug 9;7:12451. doi: 10.1038/ncomms12451.'
    evidence:
    - reference: PMID:27501781
      reference_title: Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2016 Aug 9;7:12451. doi: 10.1038/ncomms12451.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:32700450
  title: Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2020 Aug;4(8):e2000110. doi: 10.1002/adbi.202000110.'
    supporting_text: '2020 Aug;4(8):e2000110. doi: 10.1002/adbi.202000110.'
    evidence:
    - reference: PMID:32700450
      reference_title: Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2020 Aug;4(8):e2000110. doi: 10.1002/adbi.202000110.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:32954743
  title: 'Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR)TKI.
    supporting_text: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR)TKI.
    evidence:
    - reference: PMID:32954743
      reference_title: 'Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR)TKI.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:33079008
  title: Frequency and types of EGFR mutations in Moroccan patients with non-small cell lung cancer.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma histology.
    supporting_text: Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma histology.
    evidence:
    - reference: PMID:33079008
      reference_title: Frequency and types of EGFR mutations in Moroccan patients with non-small cell lung cancer.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma histology.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:33148913
  title: Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2020;67(3.4):343-350. doi: 10.2152/jmi.67.343.'
    supporting_text: '2020;67(3.4):343-350. doi: 10.2152/jmi.67.343.'
    evidence:
    - reference: PMID:33148913
      reference_title: Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2020;67(3.4):343-350. doi: 10.2152/jmi.67.343.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:34295687
  title: 'Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Treatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been changed by the advent of tyrosine kinase inhibitors (TKIs).
    supporting_text: Treatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been changed by the advent of tyrosine kinase inhibitors (TKIs).
    evidence:
    - reference: PMID:34295687
      reference_title: 'Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Treatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been changed by the advent of tyrosine kinase inhibitors (TKIs).
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:34531539
  title: Identifying transcriptional programs underlying cancer drug response with TraCe-seq.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2022 Jan;40(1):86-93. doi: 10.1038/s41587-021-01005-3.'
    supporting_text: '2022 Jan;40(1):86-93. doi: 10.1038/s41587-021-01005-3.'
    evidence:
    - reference: PMID:34531539
      reference_title: Identifying transcriptional programs underlying cancer drug response with TraCe-seq.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: '2022 Jan;40(1):86-93. doi: 10.1038/s41587-021-01005-3.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:34722761
  title: 'Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable in EGFR-mutant non-small-cell lung cancer (NSCLC) patients.
    supporting_text: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable in EGFR-mutant non-small-cell lung cancer (NSCLC) patients.
    evidence:
    - reference: PMID:34722761
      reference_title: 'Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable in EGFR-mutant non-small-cell lung cancer (NSCLC) patients.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:34994616
  title: EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2021 Nov;5:839-848. doi: 10.1200/PO.20.00404.'
    supporting_text: '2021 Nov;5:839-848. doi: 10.1200/PO.20.00404.'
    evidence:
    - reference: PMID:34994616
      reference_title: EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2021 Nov;5:839-848. doi: 10.1200/PO.20.00404.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:35308511
  title: 'PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2022 Mar 3;9:822200. doi: 10.3389/fmed.2022.822200. eCollection 2022.'
    supporting_text: '2022 Mar 3;9:822200. doi: 10.3389/fmed.2022.822200. eCollection 2022.'
    evidence:
    - reference: PMID:35308511
      reference_title: 'PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2022 Mar 3;9:822200. doi: 10.3389/fmed.2022.822200. eCollection 2022.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:35343188
  title: 'CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Molecular tissue testing in non-small cell lung cancer (NSCLC) is done for the assessment of epidermal growth factor receptor (EGFR) mutation.
    supporting_text: Molecular tissue testing in non-small cell lung cancer (NSCLC) is done for the assessment of epidermal growth factor receptor (EGFR) mutation.
    evidence:
    - reference: PMID:35343188
      reference_title: 'CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Molecular tissue testing in non-small cell lung cancer (NSCLC) is done for the assessment of epidermal growth factor receptor (EGFR) mutation.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:36652172
  title: 'Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2023 Jan;18(1):9-24. doi: 10.1007/s11523-022-00941-7.'
    supporting_text: '2023 Jan;18(1):9-24. doi: 10.1007/s11523-022-00941-7.'
    evidence:
    - reference: PMID:36652172
      reference_title: 'Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2023 Jan;18(1):9-24. doi: 10.1007/s11523-022-00941-7.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:37060646
  title: 'Acquired resistance mechanisms to osimertinib: The constant battle.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2023 May;116:102557. doi: 10.1016/j.ctrv.2023.102557.'
    supporting_text: '2023 May;116:102557. doi: 10.1016/j.ctrv.2023.102557.'
    evidence:
    - reference: PMID:37060646
      reference_title: 'Acquired resistance mechanisms to osimertinib: The constant battle.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2023 May;116:102557. doi: 10.1016/j.ctrv.2023.102557.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:38461768
  title: 'Uncommon de novo EGFR(T790M)-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2024 Apr;190:107528. doi: 10.1016/j.lungcan.2024.107528.'
    supporting_text: '2024 Apr;190:107528. doi: 10.1016/j.lungcan.2024.107528.'
    evidence:
    - reference: PMID:38461768
      reference_title: 'Uncommon de novo EGFR(T790M)-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2024 Apr;190:107528. doi: 10.1016/j.lungcan.2024.107528.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:38607364
  title: Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2024 May 2;84(9):1491-1503. doi: 10.1158/0008-5472.CAN-23-1551.'
    supporting_text: '2024 May 2;84(9):1491-1503. doi: 10.1158/0008-5472.CAN-23-1551.'
    evidence:
    - reference: PMID:38607364
      reference_title: Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2024 May 2;84(9):1491-1503. doi: 10.1158/0008-5472.CAN-23-1551.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:38824269
  title: 'Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain the frontline standard of care for patients with EGFR-mutant non-small cell lung cancer.
    supporting_text: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain the frontline standard of care for patients with EGFR-mutant non-small cell lung cancer.
    evidence:
    - reference: PMID:38824269
      reference_title: 'Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain the frontline standard of care for patients with EGFR-mutant non-small cell lung cancer.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:39052387
  title: The genomic landscape of lung cancer in never-smokers from the Women's Health Initiative.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2024 Jul 25;9(17):e174643. doi: 10.1172/jci.insight.174643.'
    supporting_text: '2024 Jul 25;9(17):e174643. doi: 10.1172/jci.insight.174643.'
    evidence:
    - reference: PMID:39052387
      reference_title: The genomic landscape of lung cancer in never-smokers from the Women's Health Initiative.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2024 Jul 25;9(17):e174643. doi: 10.1172/jci.insight.174643.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:39116206
  title: Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2024 Aug 27;43(8):114613. doi: 10.1016/j.celrep.2024.114613.'
    supporting_text: '2024 Aug 27;43(8):114613. doi: 10.1016/j.celrep.2024.114613.'
    evidence:
    - reference: PMID:39116206
      reference_title: Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2024 Aug 27;43(8):114613. doi: 10.1016/j.celrep.2024.114613.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:39799785
  title: 'Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Inadequate tumour samples often hinder molecular testing in non-small cell lung cancer (NSCLC).
    supporting_text: Inadequate tumour samples often hinder molecular testing in non-small cell lung cancer (NSCLC).
    evidence:
    - reference: PMID:39799785
      reference_title: 'Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Inadequate tumour samples often hinder molecular testing in non-small cell lung cancer (NSCLC).
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:40155080
  title: '[Standard of care of EGFR mutated metastatic NSCLC in first treatment and beyond progression].'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Osimertinib is a standard first-line treatment for EGFR-mutated metastatic NSCLC.
    supporting_text: osimertinib, a third-generation TKI, has become the standard
    evidence:
    - reference: PMID:40155080
      reference_title: '[Standard of care of EGFR mutated metastatic NSCLC in first treatment and beyond progression].'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: osimertinib, a third-generation TKI, has become the standard
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:40414926
  title: Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2025 May 25;16(1):414. doi: 10.1038/s41419-025-07711-z.'
    supporting_text: '2025 May 25;16(1):414. doi: 10.1038/s41419-025-07711-z.'
    evidence:
    - reference: PMID:40414926
      reference_title: Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2025 May 25;16(1):414. doi: 10.1038/s41419-025-07711-z.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:40667612
  title: 'Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024).'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2025 Sep;35(9):963-982. doi: 10.1080/13543776.2025.2536006.'
    supporting_text: '2025 Sep;35(9):963-982. doi: 10.1080/13543776.2025.2536006.'
    evidence:
    - reference: PMID:40667612
      reference_title: 'Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024).'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2025 Sep;35(9):963-982. doi: 10.1080/13543776.2025.2536006.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:40919674
  title: 'Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2025 Sep;86(6):e70153. doi: 10.1002/ddr.70153.'
    supporting_text: '2025 Sep;86(6):e70153. doi: 10.1002/ddr.70153.'
    evidence:
    - reference: PMID:40919674
      reference_title: 'Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2025 Sep;86(6):e70153. doi: 10.1002/ddr.70153.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41145016
  title: Prognostic impact of pleural lavage cytology in EGFR-stratified resected non-small cell lung cancer.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2025 Nov;209:108804. doi: 10.1016/j.lungcan.2025.108804.'
    supporting_text: '2025 Nov;209:108804. doi: 10.1016/j.lungcan.2025.108804.'
    evidence:
    - reference: PMID:41145016
      reference_title: Prognostic impact of pleural lavage cytology in EGFR-stratified resected non-small cell lung cancer.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2025 Nov;209:108804. doi: 10.1016/j.lungcan.2025.108804.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41168822
  title: Genome-wide association, single-cell, and spatial transcriptomics analyses reveal the role of the STK24-expressing positive cells in LUAD progression and the tumor microenvironment, identifying STK24 as a potential therapeutic target.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), has high incidence and poor prognosis.
    supporting_text: Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), has high incidence and poor prognosis.
    evidence:
    - reference: PMID:41168822
      reference_title: Genome-wide association, single-cell, and spatial transcriptomics analyses reveal the role of the STK24-expressing positive cells in LUAD progression and the tumor microenvironment, identifying STK24 as a potential therapeutic target.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), has high incidence and poor prognosis.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41223879
  title: Real-world treatment outcomes in South Korean patients with epidermal growth factor receptor-mutant non-small cell lung cancer.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2025 Nov;40(6):1029-1041. doi: 10.3904/kjim.2024.047.'
    supporting_text: '2025 Nov;40(6):1029-1041. doi: 10.3904/kjim.2024.047.'
    evidence:
    - reference: PMID:41223879
      reference_title: Real-world treatment outcomes in South Korean patients with epidermal growth factor receptor-mutant non-small cell lung cancer.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2025 Nov;40(6):1029-1041. doi: 10.3904/kjim.2024.047.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41327362
  title: Clinical significance of HPV DNA and EGFR mutations in Egyptian NSCLC.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
    supporting_text: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
    evidence:
    - reference: PMID:41327362
      reference_title: Clinical significance of HPV DNA and EGFR mutations in Egyptian NSCLC.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41353641
  title: 'Long-term Follow-up of Resected EGFR-mutated Non-small Cell Lung Cancer: A Real-world Study in a Portuguese Centre.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2025 Dec 2;38(12):795-799. doi: 10.20344/amp.23507.'
    supporting_text: '2025 Dec 2;38(12):795-799. doi: 10.20344/amp.23507.'
    evidence:
    - reference: PMID:41353641
      reference_title: 'Long-term Follow-up of Resected EGFR-mutated Non-small Cell Lung Cancer: A Real-world Study in a Portuguese Centre.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2025 Dec 2;38(12):795-799. doi: 10.20344/amp.23507.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41371099
  title: 'Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2026 Jan;211:108854. doi: 10.1016/j.lungcan.2025.108854.'
    supporting_text: '2026 Jan;211:108854. doi: 10.1016/j.lungcan.2025.108854.'
    evidence:
    - reference: PMID:41371099
      reference_title: 'Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Jan;211:108854. doi: 10.1016/j.lungcan.2025.108854.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41372401
  title: Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2026 Feb;650(8100):230-241. doi: 10.1038/s41586-025-09825-y.'
    supporting_text: '2026 Feb;650(8100):230-241. doi: 10.1038/s41586-025-09825-y.'
    evidence:
    - reference: PMID:41372401
      reference_title: Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Feb;650(8100):230-241. doi: 10.1038/s41586-025-09825-y.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41430586
  title: Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: The C797S mutation is a prevalent resistance mechanism to third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).
    supporting_text: The C797S mutation is a prevalent resistance mechanism to third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).
    evidence:
    - reference: PMID:41430586
      reference_title: Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The C797S mutation is a prevalent resistance mechanism to third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41443486
  title: 'TROP-2-directed antibody-drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2026 Feb;218:105093. doi: 10.1016/j.critrevonc.2025.105093.'
    supporting_text: '2026 Feb;218:105093. doi: 10.1016/j.critrevonc.2025.105093.'
    evidence:
    - reference: PMID:41443486
      reference_title: 'TROP-2-directed antibody-drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Feb;218:105093. doi: 10.1016/j.critrevonc.2025.105093.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41479892
  title: 'Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistance.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) presenting with malignant pleural effusion (MPE) at diagnosis have a poor prognosis.
    supporting_text: Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) presenting with malignant pleural effusion (MPE) at diagnosis have a poor prognosis.
    evidence:
    - reference: PMID:41479892
      reference_title: 'Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistance.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) presenting with malignant pleural effusion (MPE) at diagnosis have a poor prognosis.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41516316
  title: Lineage Plasticity and Histologic Transformation in EGFR-TKI Resistant Lung Cancer.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2025 Dec 31;27(1):445. doi: 10.3390/ijms27010445.'
    supporting_text: '2025 Dec 31;27(1):445. doi: 10.3390/ijms27010445.'
    evidence:
    - reference: PMID:41516316
      reference_title: Lineage Plasticity and Histologic Transformation in EGFR-TKI Resistant Lung Cancer.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2025 Dec 31;27(1):445. doi: 10.3390/ijms27010445.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41520595
  title: 'Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Despite the availability of several validated therapies, the optimal second-line regimen for EGFR-mutant non-small cell lung cancer (NSCLC) after tyrosine kinase inhibitor (TKI) failure remains uncertain.
    supporting_text: Despite the availability of several validated therapies, the optimal second-line regimen for EGFR-mutant non-small cell lung cancer (NSCLC) after tyrosine kinase inhibitor (TKI) failure remains uncertain.
    evidence:
    - reference: PMID:41520595
      reference_title: 'Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Despite the availability of several validated therapies, the optimal second-line regimen for EGFR-mutant non-small cell lung cancer (NSCLC) after tyrosine kinase inhibitor (TKI) failure remains uncertain.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41617518
  title: 'Genomic profiling of early-stage resectable non-small-cell lung cancer in a Malaysian private healthcare setting: Real-world clinical implications.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Sachithanandan A(1)(2)(3), Hoh HH(4), Lam MD(5), Low EC(6), Yap NY(7), Hassanudin SA(4), Ten YY(5), Tan PK(4), Naim CK(4), Lutfi FNM(5), Yong WWS(5), Sachithananthan S(4)(8), Yap XL(4), Rajadurai P(7)(9)(10).
    supporting_text: Sachithanandan A(1)(2)(3), Hoh HH(4), Lam MD(5), Low EC(6), Yap NY(7), Hassanudin SA(4), Ten YY(5), Tan PK(4), Naim CK(4), Lutfi FNM(5), Yong WWS(5), Sachithananthan S(4)(8), Yap XL(4), Rajadurai P(7)(9)(10).
    evidence:
    - reference: PMID:41617518
      reference_title: 'Genomic profiling of early-stage resectable non-small-cell lung cancer in a Malaysian private healthcare setting: Real-world clinical implications.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Sachithanandan A(1)(2)(3), Hoh HH(4), Lam MD(5), Low EC(6), Yap NY(7), Hassanudin SA(4), Ten YY(5), Tan PK(4), Naim CK(4), Lutfi FNM(5), Yong WWS(5), Sachithananthan S(4)(8), Yap XL(4), Rajadurai P(7)(9)(10).
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41671629
  title: 'Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Epidermal growth factor receptor (EGFR) exon 20 insertions (Ex20ins) are the third most common type of EGFR mutation, occurring in up to 12% of EGFR-mutated non-small cell lung cancers (NSCLC).
    supporting_text: Epidermal growth factor receptor (EGFR) exon 20 insertions (Ex20ins) are the third most common type of EGFR mutation, occurring in up to 12% of EGFR-mutated non-small cell lung cancers (NSCLC).
    evidence:
    - reference: PMID:41671629
      reference_title: 'Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Epidermal growth factor receptor (EGFR) exon 20 insertions (Ex20ins) are the third most common type of EGFR mutation, occurring in up to 12% of EGFR-mutated non-small cell lung cancers (NSCLC).
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41785639
  title: 'Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: 'Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort'
    supporting_text: 'In the phase III LAURA study, osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor demonstrated statistically significant improvement in progression-free survival (PFS) versus placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) without progression during/after definitive chemoradiotherapy (CRT); PFS hazard ratio 0.16; 95 % confidence interval (CI): 0.10-0.24; p < 0.001.'
    evidence:
    - reference: PMID:41785639
      reference_title: 'Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: 'In the phase III LAURA study, osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor demonstrated statistically significant improvement in progression-free survival (PFS) versus placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) without progression during/after definitive chemoradiotherapy (CRT); PFS hazard ratio 0.16; 95 % confidence interval (CI): 0.10-0.24; p < 0.001.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41793321
  title: Clinicopathological and genomic features of early-onset non-small cell lung cancer across age and ethnicity.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Huang P(1), Song J(1), Liu J(2), Li Y(2), Xie J(3), Li B(4), Yang J(5), Hou J(6), Zhao Z(1).
    supporting_text: Huang P(1), Song J(1), Liu J(2), Li Y(2), Xie J(3), Li B(4), Yang J(5), Hou J(6), Zhao Z(1).
    evidence:
    - reference: PMID:41793321
      reference_title: Clinicopathological and genomic features of early-onset non-small cell lung cancer across age and ethnicity.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Huang P(1), Song J(1), Liu J(2), Li Y(2), Xie J(3), Li B(4), Yang J(5), Hou J(6), Zhao Z(1).
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41862776
  title: 'Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: The optimal treatment strategy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC)-sequential tyrosine kinase inhibitor (TKI) monotherapies versus upfront combination therapies-remains debated.
    supporting_text: The optimal treatment strategy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC)-sequential tyrosine kinase inhibitor (TKI) monotherapies versus upfront combination therapies-remains debated.
    evidence:
    - reference: PMID:41862776
      reference_title: 'Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The optimal treatment strategy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC)-sequential tyrosine kinase inhibitor (TKI) monotherapies versus upfront combination therapies-remains debated.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41907704
  title: 'Osimertinib for Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Current Evidence.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated efficacy across multiple treatment lines for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    supporting_text: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated efficacy across multiple treatment lines for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    evidence:
    - reference: PMID:41907704
      reference_title: 'Osimertinib for Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Current Evidence.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated efficacy across multiple treatment lines for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41927036
  title: Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2026 Mar 31. doi: 10.4143/crt.2025.1399.'
    supporting_text: '2026 Mar 31. doi: 10.4143/crt.2025.1399.'
    evidence:
    - reference: PMID:41927036
      reference_title: Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2026 Mar 31. doi: 10.4143/crt.2025.1399.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41932615
  title: 'Lung Cancer in Never Smokers: Genetics, Epidemiology, Environmental Exposures, and Distinct Immune Landscape.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2026 Apr 1:103709. doi: 10.1016/j.jtho.2026.103709.'
    supporting_text: '2026 Apr 1:103709. doi: 10.1016/j.jtho.2026.103709.'
    evidence:
    - reference: PMID:41932615
      reference_title: 'Lung Cancer in Never Smokers: Genetics, Epidemiology, Environmental Exposures, and Distinct Immune Landscape.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2026 Apr 1:103709. doi: 10.1016/j.jtho.2026.103709.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41933853
  title: 'Pulmonary microbiota is a hidden link between lung cancer Development and microenvironment: Potential for future immune therapeutic strategies.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2026 Mar 31;223:105308. doi: 10.1016/j.critrevonc.2026.105308.'
    supporting_text: '2026 Mar 31;223:105308. doi: 10.1016/j.critrevonc.2026.105308.'
    evidence:
    - reference: PMID:41933853
      reference_title: 'Pulmonary microbiota is a hidden link between lung cancer Development and microenvironment: Potential for future immune therapeutic strategies.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Mar 31;223:105308. doi: 10.1016/j.critrevonc.2026.105308.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41933854
  title: 'The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Lung cancer is the second most common malignancy and the leading cause of cancer-related mortality worldwide.
    supporting_text: Lung cancer is the second most common malignancy and the leading cause of cancer-related mortality worldwide.
    evidence:
    - reference: PMID:41933854
      reference_title: 'The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Lung cancer is the second most common malignancy and the leading cause of cancer-related mortality worldwide.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41965447
  title: Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2026 Apr 11. doi: 10.1038/s41388-026-03772-2.'
    supporting_text: '2026 Apr 11. doi: 10.1038/s41388-026-03772-2.'
    evidence:
    - reference: PMID:41965447
      reference_title: Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Apr 11. doi: 10.1038/s41388-026-03772-2.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41977474
  title: Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2026 Apr 5;27(7):3294. doi: 10.3390/ijms27073294.'
    supporting_text: '2026 Apr 5;27(7):3294. doi: 10.3390/ijms27073294.'
    evidence:
    - reference: PMID:41977474
      reference_title: Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Apr 5;27(7):3294. doi: 10.3390/ijms27073294.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:41985129
  title: First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Until recently, no first-line targeted treatment options were available for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC).
    supporting_text: Until recently, no first-line targeted treatment options were available for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC).
    evidence:
    - reference: PMID:41985129
      reference_title: First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Until recently, no first-line targeted treatment options were available for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC).
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:42033967
  title: 'Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2026 Apr 19;146:103138. doi: 10.1016/j.ctrv.2026.103138.'
    supporting_text: '2026 Apr 19;146:103138. doi: 10.1016/j.ctrv.2026.103138.'
    evidence:
    - reference: PMID:42033967
      reference_title: 'Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Apr 19;146:103138. doi: 10.1016/j.ctrv.2026.103138.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:42049362
  title: 'Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: '2026 May;46(5):2781-2788. doi: 10.21873/anticanres.18158.'
    supporting_text: '2026 May;46(5):2781-2788. doi: 10.21873/anticanres.18158.'
    evidence:
    - reference: PMID:42049362
      reference_title: 'Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2026 May;46(5):2781-2788. doi: 10.21873/anticanres.18158.'
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:42087187
  title: 'Unmasking the common enemy: drug resistance mechanisms across three different EGFR inhibitor generations are associated with co-targetable alterations in extracellular matrix signaling.'
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have transformed non-small cell lung cancer (NSCLC) treatment, offering substantial survival benefits.
    supporting_text: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have transformed non-small cell lung cancer (NSCLC) treatment, offering substantial survival benefits.
    evidence:
    - reference: PMID:42087187
      reference_title: 'Unmasking the common enemy: drug resistance mechanisms across three different EGFR inhibitor generations are associated with co-targetable alterations in extracellular matrix signaling.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have transformed non-small cell lung cancer (NSCLC) treatment, offering substantial survival benefits.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.
- reference: PMID:7478577
  title: Activation of the EGF receptor by insertional mutations in its juxtamembrane regions.
  found_in:
  - EGFR_Mutant_NSCLC-deep-research-openscientist.md
  findings:
  - statement: Ligand dependent activation of receptor tyrosine kinases is mediated by an allosteric dimerization process that is responsible for the stimulation of protein tyrosine kinase activity and receptor autophosphorylation.
    supporting_text: Ligand dependent activation of receptor tyrosine kinases is mediated by an allosteric dimerization process that is responsible for the stimulation of protein tyrosine kinase activity and receptor autophosphorylation.
    evidence:
    - reference: PMID:7478577
      reference_title: Activation of the EGF receptor by insertional mutations in its juxtamembrane regions.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Ligand dependent activation of receptor tyrosine kinases is mediated by an allosteric dimerization process that is responsible for the stimulation of protein tyrosine kinase activity and receptor autophosphorylation.
      explanation: Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

📚

References & Deep Research

References

DOI:10.1016/j.jncc.2024.06.004

Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review

1 finding

Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review

"Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review"

DOI:10.1016/j.pccm.2024.08.002

Overcoming EGFR-TKI resistance by targeting the tumor microenvironment

1 finding

Overcoming EGFR-TKI resistance by targeting the tumor microenvironment

"Overcoming EGFR-TKI resistance by targeting the tumor microenvironment"

DOI:10.1038/s41417-024-00761-z

Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers

1 finding

Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell lung cancer (NSCLC) constitutes around 85% of all lung cancer cases.

"Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell lung cancer (NSCLC) constitutes around 85% of all lung cancer cases."

Show evidence (1 reference)

DOI:10.1038/s41417-024-00761-z SUPPORT Human Clinical

"Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell lung cancer (NSCLC) constitutes around 85% of all lung cancer cases."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

DOI:10.1038/s41418-024-01317-2

PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy

1 finding

PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy

"PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy"

DOI:10.1038/s41419-024-06945-7

PD-L1 induces autophagy and primary resistance to EGFR–TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway

1 finding

Resistance to epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) is a significant cause of treatment failure and cancer recurrence in non-small cell lung cancer (NSCLC).

"Resistance to epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) is a significant cause of treatment failure and cancer recurrence in non-small cell lung cancer (NSCLC)."

Show evidence (1 reference)

DOI:10.1038/s41419-024-06945-7 SUPPORT Human Clinical

"Resistance to epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) is a significant cause of treatment failure and cancer recurrence in non-small cell lung cancer (NSCLC)."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

DOI:10.1080/14728222.2023.2218613

Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?

1 finding

Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?

"Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?"

DOI:10.1186/s12943-023-01780-4

Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer

1 finding

RNA 5-methylcytosine (m5C) modification plays critical roles in the pathogenesis of various tumors.

"RNA 5-methylcytosine (m5C) modification plays critical roles in the pathogenesis of various tumors."

Show evidence (1 reference)

DOI:10.1186/s12943-023-01780-4 SUPPORT Human Clinical

"RNA 5-methylcytosine (m5C) modification plays critical roles in the pathogenesis of various tumors."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

DOI:10.21037/tlcr-23-98

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates

1 finding

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates

"EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates"

DOI:10.32604/or.2025.059311

Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies

1 finding

Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies

"Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies"

DOI:10.3390/biomedicines13020470

Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges

1 finding

Tyrosine kinase inhibitors (TKIs) have transformed the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer.

"Tyrosine kinase inhibitors (TKIs) have transformed the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer."

Show evidence (1 reference)

DOI:10.3390/biomedicines13020470 SUPPORT Other

"Tyrosine kinase inhibitors (TKIs) have transformed the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

DOI:10.3390/ijms25115917

Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer

1 finding

Non-small-cell lung cancer (NSCLC) frequently harbors mutations in the epidermal growth factor receptor (EGFR), with exon 20 insertions comprising 1–10% of these mutations.

"Non-small-cell lung cancer (NSCLC) frequently harbors mutations in the epidermal growth factor receptor (EGFR), with exon 20 insertions comprising 1–10% of these mutations."

Show evidence (1 reference)

DOI:10.3390/ijms25115917 SUPPORT Other

"Non-small-cell lung cancer (NSCLC) frequently harbors mutations in the epidermal growth factor receptor (EGFR), with exon 20 insertions comprising 1–10% of these mutations."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

DOI:10.3390/ijms26072957

Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer

1 finding

Non-small-cell lung cancer (NSCLC) represents the most common type of lung cancer.

"Non-small-cell lung cancer (NSCLC) represents the most common type of lung cancer."

Show evidence (1 reference)

DOI:10.3390/ijms26072957 SUPPORT Human Clinical

"Non-small-cell lung cancer (NSCLC) represents the most common type of lung cancer."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

DOI:10.3892/ol.2025.15121

EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)

1 finding

EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)

"EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)"

DOI:10.62347/wtmu5537

New advances in the treatment of EGFR exon20ins mutant advanced NSCLC

1 finding

New advances in the treatment of EGFR exon20ins mutant advanced NSCLC

"New advances in the treatment of EGFR exon20ins mutant advanced NSCLC"

PMID:16989002

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.

1 finding

Chemonaive patients had higher response rates than chemotherapy-treated patients in previous analyses of East Asian patients with advanced nonsmall cell lung cancer.

"Chemonaive patients had higher response rates than chemotherapy-treated patients in previous analyses of East Asian patients with advanced nonsmall cell lung cancer."

Show evidence (1 reference)

PMID:16989002 SUPPORT Human Clinical

"Chemonaive patients had higher response rates than chemotherapy-treated patients in previous analyses of East Asian patients with advanced nonsmall cell lung cancer."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:21527061

East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.

1 finding

2011 May;30(5):287-92. doi: 10.5732/cjc.011.10106.

"2011 May;30(5):287-92. doi: 10.5732/cjc.011.10106."

Show evidence (1 reference)

PMID:21527061 SUPPORT Other

"2011 May;30(5):287-92. doi: 10.5732/cjc.011.10106."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:23299280

Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung.

1 finding

Worldwide studies on lung adenocarcinoma have demonstrated a genetic divergence of the epidermal growth factor receptor (EGFR) pathway according to ethnicity, such as higher frequency of activated EGFR mutations among East Asian patients.

"Worldwide studies on lung adenocarcinoma have demonstrated a genetic divergence of the epidermal growth factor receptor (EGFR) pathway according to ethnicity, such as higher frequency of activated EGFR mutations among East Asian patients."

Show evidence (1 reference)

PMID:23299280 SUPPORT Human Clinical

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:27501781

Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma.

1 finding

2016 Aug 9;7:12451. doi: 10.1038/ncomms12451.

"2016 Aug 9;7:12451. doi: 10.1038/ncomms12451."

Show evidence (1 reference)

PMID:27501781 SUPPORT Other

"2016 Aug 9;7:12451. doi: 10.1038/ncomms12451."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:32700450

Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC.

1 finding

2020 Aug;4(8):e2000110. doi: 10.1002/adbi.202000110.

"2020 Aug;4(8):e2000110. doi: 10.1002/adbi.202000110."

Show evidence (1 reference)

PMID:32700450 SUPPORT Human Clinical

"2020 Aug;4(8):e2000110. doi: 10.1002/adbi.202000110."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:32954743

Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review.

1 finding

Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR)TKI.

"Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR)TKI."

Show evidence (1 reference)

PMID:32954743 SUPPORT Other

"Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR)TKI."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:33079008

Frequency and types of EGFR mutations in Moroccan patients with non-small cell lung cancer.

1 finding

Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma histology.

"Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma histology."

Show evidence (1 reference)

PMID:33079008 SUPPORT Human Clinical

"Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma histology."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:33148913

Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.

1 finding

2020;67(3.4):343-350. doi: 10.2152/jmi.67.343.

"2020;67(3.4):343-350. doi: 10.2152/jmi.67.343."

Show evidence (1 reference)

PMID:33148913 SUPPORT Human Clinical

"2020;67(3.4):343-350. doi: 10.2152/jmi.67.343."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:34295687

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.

1 finding

Treatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been changed by the advent of tyrosine kinase inhibitors (TKIs).

"Treatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been changed by the advent of tyrosine kinase inhibitors (TKIs)."

Show evidence (1 reference)

PMID:34295687 SUPPORT Other

"Treatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been changed by the advent of tyrosine kinase inhibitors (TKIs)."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:34531539

Identifying transcriptional programs underlying cancer drug response with TraCe-seq.

1 finding

2022 Jan;40(1):86-93. doi: 10.1038/s41587-021-01005-3.

"2022 Jan;40(1):86-93. doi: 10.1038/s41587-021-01005-3."

Show evidence (1 reference)

PMID:34531539 SUPPORT In Vitro

"2022 Jan;40(1):86-93. doi: 10.1038/s41587-021-01005-3."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:34722761

Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis.

1 finding

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable in EGFR-mutant non-small-cell lung cancer (NSCLC) patients.

"Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable in EGFR-mutant non-small-cell lung cancer (NSCLC) patients."

Show evidence (1 reference)

PMID:34722761 SUPPORT Other

"Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable in EGFR-mutant non-small-cell lung cancer (NSCLC) patients."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:34994616

EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).

1 finding

2021 Nov;5:839-848. doi: 10.1200/PO.20.00404.

"2021 Nov;5:839-848. doi: 10.1200/PO.20.00404."

Show evidence (1 reference)

PMID:34994616 SUPPORT Other

"2021 Nov;5:839-848. doi: 10.1200/PO.20.00404."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:35308511

PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen.

1 finding

2022 Mar 3;9:822200. doi: 10.3389/fmed.2022.822200. eCollection 2022.

"2022 Mar 3;9:822200. doi: 10.3389/fmed.2022.822200. eCollection 2022."

Show evidence (1 reference)

PMID:35308511 SUPPORT Other

"2022 Mar 3;9:822200. doi: 10.3389/fmed.2022.822200. eCollection 2022."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:35343188

CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.

1 finding

Molecular tissue testing in non-small cell lung cancer (NSCLC) is done for the assessment of epidermal growth factor receptor (EGFR) mutation.

"Molecular tissue testing in non-small cell lung cancer (NSCLC) is done for the assessment of epidermal growth factor receptor (EGFR) mutation."

Show evidence (1 reference)

PMID:35343188 SUPPORT Other

"Molecular tissue testing in non-small cell lung cancer (NSCLC) is done for the assessment of epidermal growth factor receptor (EGFR) mutation."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:36652172

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.

1 finding

2023 Jan;18(1):9-24. doi: 10.1007/s11523-022-00941-7.

"2023 Jan;18(1):9-24. doi: 10.1007/s11523-022-00941-7."

Show evidence (1 reference)

PMID:36652172 SUPPORT Human Clinical

"2023 Jan;18(1):9-24. doi: 10.1007/s11523-022-00941-7."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:37060646

Acquired resistance mechanisms to osimertinib: The constant battle.

1 finding

2023 May;116:102557. doi: 10.1016/j.ctrv.2023.102557.

"2023 May;116:102557. doi: 10.1016/j.ctrv.2023.102557."

Show evidence (1 reference)

PMID:37060646 SUPPORT Other

"2023 May;116:102557. doi: 10.1016/j.ctrv.2023.102557."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:38461768

Uncommon de novo EGFR(T790M)-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment.

1 finding

2024 Apr;190:107528. doi: 10.1016/j.lungcan.2024.107528.

"2024 Apr;190:107528. doi: 10.1016/j.lungcan.2024.107528."

Show evidence (1 reference)

PMID:38461768 SUPPORT Other

"2024 Apr;190:107528. doi: 10.1016/j.lungcan.2024.107528."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:38607364

Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations.

1 finding

2024 May 2;84(9):1491-1503. doi: 10.1158/0008-5472.CAN-23-1551.

"2024 May 2;84(9):1491-1503. doi: 10.1158/0008-5472.CAN-23-1551."

Show evidence (1 reference)

PMID:38607364 SUPPORT Human Clinical

"2024 May 2;84(9):1491-1503. doi: 10.1158/0008-5472.CAN-23-1551."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:38824269

Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.

1 finding

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain the frontline standard of care for patients with EGFR-mutant non-small cell lung cancer.

"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain the frontline standard of care for patients with EGFR-mutant non-small cell lung cancer."

Show evidence (1 reference)

PMID:38824269 SUPPORT Other

"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain the frontline standard of care for patients with EGFR-mutant non-small cell lung cancer."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:39052387

The genomic landscape of lung cancer in never-smokers from the Women's Health Initiative.

1 finding

2024 Jul 25;9(17):e174643. doi: 10.1172/jci.insight.174643.

"2024 Jul 25;9(17):e174643. doi: 10.1172/jci.insight.174643."

Show evidence (1 reference)

PMID:39052387 SUPPORT Other

"2024 Jul 25;9(17):e174643. doi: 10.1172/jci.insight.174643."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:39116206

Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.

1 finding

2024 Aug 27;43(8):114613. doi: 10.1016/j.celrep.2024.114613.

"2024 Aug 27;43(8):114613. doi: 10.1016/j.celrep.2024.114613."

Show evidence (1 reference)

PMID:39116206 SUPPORT Other

"2024 Aug 27;43(8):114613. doi: 10.1016/j.celrep.2024.114613."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:39799785

Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study.

1 finding

Inadequate tumour samples often hinder molecular testing in non-small cell lung cancer (NSCLC).

"Inadequate tumour samples often hinder molecular testing in non-small cell lung cancer (NSCLC)."

Show evidence (1 reference)

PMID:39799785 SUPPORT Other

"Inadequate tumour samples often hinder molecular testing in non-small cell lung cancer (NSCLC)."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:40155080

[Standard of care of EGFR mutated metastatic NSCLC in first treatment and beyond progression].

1 finding

Osimertinib is a standard first-line treatment for EGFR-mutated metastatic NSCLC.

"osimertinib, a third-generation TKI, has become the standard"

Show evidence (1 reference)

PMID:40155080 SUPPORT Other

"osimertinib, a third-generation TKI, has become the standard"

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:40414926

Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer.

1 finding

2025 May 25;16(1):414. doi: 10.1038/s41419-025-07711-z.

"2025 May 25;16(1):414. doi: 10.1038/s41419-025-07711-z."

Show evidence (1 reference)

PMID:40414926 SUPPORT Other

"2025 May 25;16(1):414. doi: 10.1038/s41419-025-07711-z."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:40667612

Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024).

1 finding

2025 Sep;35(9):963-982. doi: 10.1080/13543776.2025.2536006.

"2025 Sep;35(9):963-982. doi: 10.1080/13543776.2025.2536006."

Show evidence (1 reference)

PMID:40667612 SUPPORT Human Clinical

"2025 Sep;35(9):963-982. doi: 10.1080/13543776.2025.2536006."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:40919674

Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer.

1 finding

2025 Sep;86(6):e70153. doi: 10.1002/ddr.70153.

"2025 Sep;86(6):e70153. doi: 10.1002/ddr.70153."

Show evidence (1 reference)

PMID:40919674 SUPPORT Human Clinical

"2025 Sep;86(6):e70153. doi: 10.1002/ddr.70153."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41145016

Prognostic impact of pleural lavage cytology in EGFR-stratified resected non-small cell lung cancer.

1 finding

2025 Nov;209:108804. doi: 10.1016/j.lungcan.2025.108804.

"2025 Nov;209:108804. doi: 10.1016/j.lungcan.2025.108804."

Show evidence (1 reference)

PMID:41145016 SUPPORT Other

"2025 Nov;209:108804. doi: 10.1016/j.lungcan.2025.108804."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41168822

Genome-wide association, single-cell, and spatial transcriptomics analyses reveal the role of the STK24-expressing positive cells in LUAD progression and the tumor microenvironment, identifying STK24 as a potential therapeutic target.

1 finding

Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), has high incidence and poor prognosis.

"Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), has high incidence and poor prognosis."

Show evidence (1 reference)

PMID:41168822 SUPPORT Other

"Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), has high incidence and poor prognosis."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41223879

Real-world treatment outcomes in South Korean patients with epidermal growth factor receptor-mutant non-small cell lung cancer.

1 finding

2025 Nov;40(6):1029-1041. doi: 10.3904/kjim.2024.047.

"2025 Nov;40(6):1029-1041. doi: 10.3904/kjim.2024.047."

Show evidence (1 reference)

PMID:41223879 SUPPORT Other

"2025 Nov;40(6):1029-1041. doi: 10.3904/kjim.2024.047."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41327362

Clinical significance of HPV DNA and EGFR mutations in Egyptian NSCLC.

1 finding

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.

"Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide."

Show evidence (1 reference)

PMID:41327362 SUPPORT Other

"Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41353641

Long-term Follow-up of Resected EGFR-mutated Non-small Cell Lung Cancer: A Real-world Study in a Portuguese Centre.

1 finding

2025 Dec 2;38(12):795-799. doi: 10.20344/amp.23507.

"2025 Dec 2;38(12):795-799. doi: 10.20344/amp.23507."

Show evidence (1 reference)

PMID:41353641 SUPPORT Human Clinical

"2025 Dec 2;38(12):795-799. doi: 10.20344/amp.23507."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41371099

Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.

1 finding

2026 Jan;211:108854. doi: 10.1016/j.lungcan.2025.108854.

"2026 Jan;211:108854. doi: 10.1016/j.lungcan.2025.108854."

Show evidence (1 reference)

PMID:41371099 SUPPORT Other

"2026 Jan;211:108854. doi: 10.1016/j.lungcan.2025.108854."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41372401

Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma.

1 finding

2026 Feb;650(8100):230-241. doi: 10.1038/s41586-025-09825-y.

"2026 Feb;650(8100):230-241. doi: 10.1038/s41586-025-09825-y."

Show evidence (1 reference)

PMID:41372401 SUPPORT Other

"2026 Feb;650(8100):230-241. doi: 10.1038/s41586-025-09825-y."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41430586

Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors.

1 finding

The C797S mutation is a prevalent resistance mechanism to third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).

"The C797S mutation is a prevalent resistance mechanism to third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC)."

Show evidence (1 reference)

PMID:41430586 SUPPORT Other

"The C797S mutation is a prevalent resistance mechanism to third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC)."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41443486

TROP-2-directed antibody-drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes.

1 finding

2026 Feb;218:105093. doi: 10.1016/j.critrevonc.2025.105093.

"2026 Feb;218:105093. doi: 10.1016/j.critrevonc.2025.105093."

Show evidence (1 reference)

PMID:41443486 SUPPORT Other

"2026 Feb;218:105093. doi: 10.1016/j.critrevonc.2025.105093."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41479892

Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistance.

1 finding

Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) presenting with malignant pleural effusion (MPE) at diagnosis have a poor prognosis.

"Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) presenting with malignant pleural effusion (MPE) at diagnosis have a poor prognosis."

Show evidence (1 reference)

PMID:41479892 SUPPORT Other

"Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) presenting with malignant pleural effusion (MPE) at diagnosis have a poor prognosis."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41516316

Lineage Plasticity and Histologic Transformation in EGFR-TKI Resistant Lung Cancer.

1 finding

2025 Dec 31;27(1):445. doi: 10.3390/ijms27010445.

"2025 Dec 31;27(1):445. doi: 10.3390/ijms27010445."

Show evidence (1 reference)

PMID:41516316 SUPPORT Other

"2025 Dec 31;27(1):445. doi: 10.3390/ijms27010445."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41520595

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis.

1 finding

Despite the availability of several validated therapies, the optimal second-line regimen for EGFR-mutant non-small cell lung cancer (NSCLC) after tyrosine kinase inhibitor (TKI) failure remains uncertain.

"Despite the availability of several validated therapies, the optimal second-line regimen for EGFR-mutant non-small cell lung cancer (NSCLC) after tyrosine kinase inhibitor (TKI) failure remains uncertain."

Show evidence (1 reference)

PMID:41520595 SUPPORT Other

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41617518

Genomic profiling of early-stage resectable non-small-cell lung cancer in a Malaysian private healthcare setting: Real-world clinical implications.

1 finding

Sachithanandan A(1)(2)(3), Hoh HH(4), Lam MD(5), Low EC(6), Yap NY(7), Hassanudin SA(4), Ten YY(5), Tan PK(4), Naim CK(4), Lutfi FNM(5), Yong WWS(5), Sachithananthan S(4)(8), Yap XL(4), Rajadurai P(7)(9)(10).

"Sachithanandan A(1)(2)(3), Hoh HH(4), Lam MD(5), Low EC(6), Yap NY(7), Hassanudin SA(4), Ten YY(5), Tan PK(4), Naim CK(4), Lutfi FNM(5), Yong WWS(5), Sachithananthan S(4)(8), Yap XL(4), Rajadurai P(7)(9)(10)."

Show evidence (1 reference)

PMID:41617518 SUPPORT Human Clinical

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41671629

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.

1 finding

Epidermal growth factor receptor (EGFR) exon 20 insertions (Ex20ins) are the third most common type of EGFR mutation, occurring in up to 12% of EGFR-mutated non-small cell lung cancers (NSCLC).

"Epidermal growth factor receptor (EGFR) exon 20 insertions (Ex20ins) are the third most common type of EGFR mutation, occurring in up to 12% of EGFR-mutated non-small cell lung cancers (NSCLC)."

Show evidence (1 reference)

PMID:41671629 SUPPORT Other

"Epidermal growth factor receptor (EGFR) exon 20 insertions (Ex20ins) are the third most common type of EGFR mutation, occurring in up to 12% of EGFR-mutated non-small cell lung cancers (NSCLC)."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41785639

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.

1 finding

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort

"In the phase III LAURA study, osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor demonstrated statistically significant improvement in progression-free survival (PFS) versus placebo in patients with unresectable stage III EGFR-mutated non-small cell..."

Show evidence (1 reference)

PMID:41785639 SUPPORT Other

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41793321

Clinicopathological and genomic features of early-onset non-small cell lung cancer across age and ethnicity.

1 finding

Huang P(1), Song J(1), Liu J(2), Li Y(2), Xie J(3), Li B(4), Yang J(5), Hou J(6), Zhao Z(1).

"Huang P(1), Song J(1), Liu J(2), Li Y(2), Xie J(3), Li B(4), Yang J(5), Hou J(6), Zhao Z(1)."

Show evidence (1 reference)

PMID:41793321 SUPPORT Human Clinical

"Huang P(1), Song J(1), Liu J(2), Li Y(2), Xie J(3), Li B(4), Yang J(5), Hou J(6), Zhao Z(1)."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41862776

Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

1 finding

The optimal treatment strategy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC)-sequential tyrosine kinase inhibitor (TKI) monotherapies versus upfront combination therapies-remains debated.

"The optimal treatment strategy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC)-sequential tyrosine kinase inhibitor (TKI) monotherapies versus upfront combination therapies-remains debated."

Show evidence (1 reference)

PMID:41862776 SUPPORT Other

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41907704

Osimertinib for Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Current Evidence.

1 finding

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated efficacy across multiple treatment lines for patients with EGFR-mutated non-small cell lung cancer (NSCLC).

"Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated efficacy across multiple treatment lines for patients with EGFR-mutated non-small cell lung cancer (NSCLC)."

Show evidence (1 reference)

PMID:41907704 SUPPORT Other

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41927036

Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC.

1 finding

2026 Mar 31. doi: 10.4143/crt.2025.1399.

"2026 Mar 31. doi: 10.4143/crt.2025.1399."

Show evidence (1 reference)

PMID:41927036 SUPPORT Human Clinical

"2026 Mar 31. doi: 10.4143/crt.2025.1399."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41932615

Lung Cancer in Never Smokers: Genetics, Epidemiology, Environmental Exposures, and Distinct Immune Landscape.

1 finding

2026 Apr 1:103709. doi: 10.1016/j.jtho.2026.103709.

"2026 Apr 1:103709. doi: 10.1016/j.jtho.2026.103709."

Show evidence (1 reference)

PMID:41932615 SUPPORT Human Clinical

"2026 Apr 1:103709. doi: 10.1016/j.jtho.2026.103709."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41933853

Pulmonary microbiota is a hidden link between lung cancer Development and microenvironment: Potential for future immune therapeutic strategies.

1 finding

2026 Mar 31;223:105308. doi: 10.1016/j.critrevonc.2026.105308.

"2026 Mar 31;223:105308. doi: 10.1016/j.critrevonc.2026.105308."

Show evidence (1 reference)

PMID:41933853 SUPPORT Other

"2026 Mar 31;223:105308. doi: 10.1016/j.critrevonc.2026.105308."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41933854

The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications.

1 finding

Lung cancer is the second most common malignancy and the leading cause of cancer-related mortality worldwide.

"Lung cancer is the second most common malignancy and the leading cause of cancer-related mortality worldwide."

Show evidence (1 reference)

PMID:41933854 SUPPORT Other

"Lung cancer is the second most common malignancy and the leading cause of cancer-related mortality worldwide."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41965447

Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer.

1 finding

2026 Apr 11. doi: 10.1038/s41388-026-03772-2.

"2026 Apr 11. doi: 10.1038/s41388-026-03772-2."

Show evidence (1 reference)

PMID:41965447 SUPPORT Other

"2026 Apr 11. doi: 10.1038/s41388-026-03772-2."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41977474

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.

1 finding

2026 Apr 5;27(7):3294. doi: 10.3390/ijms27073294.

"2026 Apr 5;27(7):3294. doi: 10.3390/ijms27073294."

Show evidence (1 reference)

PMID:41977474 SUPPORT Other

"2026 Apr 5;27(7):3294. doi: 10.3390/ijms27073294."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:41985129

First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

1 finding

Until recently, no first-line targeted treatment options were available for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC).

"Until recently, no first-line targeted treatment options were available for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC)."

Show evidence (1 reference)

PMID:41985129 SUPPORT Human Clinical

"Until recently, no first-line targeted treatment options were available for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC)."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:42033967

Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making.

1 finding

2026 Apr 19;146:103138. doi: 10.1016/j.ctrv.2026.103138.

"2026 Apr 19;146:103138. doi: 10.1016/j.ctrv.2026.103138."

Show evidence (1 reference)

PMID:42033967 SUPPORT Other

"2026 Apr 19;146:103138. doi: 10.1016/j.ctrv.2026.103138."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:42049362

Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study.

1 finding

2026 May;46(5):2781-2788. doi: 10.21873/anticanres.18158.

"2026 May;46(5):2781-2788. doi: 10.21873/anticanres.18158."

Show evidence (1 reference)

PMID:42049362 SUPPORT Human Clinical

"2026 May;46(5):2781-2788. doi: 10.21873/anticanres.18158."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:42087187

Unmasking the common enemy: drug resistance mechanisms across three different EGFR inhibitor generations are associated with co-targetable alterations in extracellular matrix signaling.

1 finding

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have transformed non-small cell lung cancer (NSCLC) treatment, offering substantial survival benefits.

"Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have transformed non-small cell lung cancer (NSCLC) treatment, offering substantial survival benefits."

Show evidence (1 reference)

PMID:42087187 SUPPORT Other

"Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have transformed non-small cell lung cancer (NSCLC) treatment, offering substantial survival benefits."

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

PMID:7478577

Activation of the EGF receptor by insertional mutations in its juxtamembrane regions.

1 finding

Ligand dependent activation of receptor tyrosine kinases is mediated by an allosteric dimerization process that is responsible for the stimulation of protein tyrosine kinase activity and receptor autophosphorylation.

"Ligand dependent activation of receptor tyrosine kinases is mediated by an allosteric dimerization process that is responsible for the stimulation of protein tyrosine kinase activity and receptor autophosphorylation."

Show evidence (1 reference)

PMID:7478577 SUPPORT Other

Deep research cited this publication as relevant literature for EGFR Mutant NSCLC.

Deep Research

Disorder ▸

Disorder

Name: EGFR-Mutant Non-Small Cell Lung Cancer
Category:
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 17

Key Pathophysiology Nodes

EGFR Oncogenic Mutations
Constitutive EGFR Signaling
Oncogene Addiction
TKI Resistance Mechanisms
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1016/j.jncc.2024.06.004
DOI:10.1016/j.pccm.2024.08.002
DOI:10.1038/s41417-024-00761-z
DOI:10.1038/s41418-024-01317-2
DOI:10.1038/s41419-024-06945-7
DOI:10.1080/14728222.2023.2218613
DOI:10.1186/s12943-023-01780-4
DOI:10.21037/tlcr-23-98
DOI:10.32604/or.2025.059311
DOI:10.3390/biomedicines13020470
DOI:10.3390/ijms25115917
DOI:10.3390/ijms26072957
DOI:10.3892/ol.2025.15121
DOI:10.62347/wtmu5537

Falcon ▸

Pathophysiology description

Edison Scientific Literature 33 citations 2026-01-24T18:51:50.113603

Pathophysiology description EGFR-mutant NSCLC is driven by activating mutations in EGFR (most commonly exon 19 deletions and exon 21 L858R), which cause constitutive kinase activation, ligand-independent dimerization, and chronic propagation of key oncogenic cascades including RAS/RAF/MEK/ERK (MAPK), PI3K/AKT/mTOR, and JAK/STAT (notably STAT3). These programs enforce proliferation, survival, and metastatic competence and establish oncogene addiction to EGFR signaling, explaining the initial sensitivity to EGFR tyrosine kinase inhibitors (TKIs) (first/second/third generation). Resistance emerges via on-target tertiary EGFR mutations (e.g., C797S after osimertinib), activation of bypass receptor tyrosine kinases (RTKs; MET and ERBB2/HER2 amplification), downstream pathway alterations, oncogenic fusions, and lineage plasticity (epithelial–mesenchymal transition [EMT] and histologic transformation). The tumor microenvironment (TME) is characteristically immunosuppressed, with impaired antigen presentation (HLA-I), enrichment of regulatory T cells (Tregs), and myeloid programs that collectively underlie the relatively poor efficacy of PD-1/PD-L1 blockade in this genotype. Recent work highlights epitranscriptomic and immune-checkpoint–driven mechanisms of primary and acquired resistance (NSUN2/YBX1/QSOX1 m5C axis; PD-L1–induced autophagy; PD-L2 upregulation), and a distinct biology of EGFR exon 20 insertions (ex20ins) that are less responsive to classical TKIs but targetable with newer agents and bispecific antibodies. (halder2023targetingtheegfr pages 4-6, zhang2024overcomingegfrtkiresistance pages 1-2, lim2025targetingthetumor pages 2-3, romaniello2025strategiestoovercome pages 1-2, li2025multimodalomicsanalysis pages 1-2)

Category	Entity (symbol/name)	Ontology IDs	Role in EGFRm NSCLC	Key 2023–2024 Evidence (DOI URL, year)
Receptor (driver)	EGFR (EGFR)	HGNC:3236; GO:0007169	Primary oncogenic driver; oncogene addiction; target of successive-generation TKIs	https://doi.org/10.1080/14728222.2023.2218613 (2023) (halder2023targetingtheegfr pages 4-6)
Pathway (proliferation)	MAPK cascade (RAS/RAF/MEK/ERK)	GO:0000165	Mediates proliferation & differentiation downstream of EGFR	https://doi.org/10.1080/14728222.2023.2218613 (2023) (halder2023targetingtheegfr pages 4-6)
Pathway (survival/metabolism)	PI3K–AKT–mTOR	GO:0014065	Promotes survival, metabolic rewiring and contributes to TKI resistance when reactivated	https://doi.org/10.1016/j.pccm.2024.08.002 (2024) (zhang2024overcomingegfrtkiresistance pages 1-2)
Pathway (inflammatory/survival)	JAK–STAT (STAT3)	GO:0007259; HGNC:11364	Drives pro-survival / immune-modulatory programs downstream of EGFR	https://doi.org/10.1080/14728222.2023.2218613 (2023) (halder2023targetingtheegfr pages 4-6)
Bypass RTK (resistance)	MET (MET)	HGNC:7029	MET amplification/overexpression is a frequent EGFR‑independent bypass causing osimertinib resistance; targetable clinically	https://doi.org/10.1016/j.pccm.2024.08.002 (2024) (zhang2024overcomingegfrtkiresistance pages 1-2)
Bypass RTK (resistance)	ERBB2 / HER2 (ERBB2)	HGNC:3430	HER2 amplification or activation can bypass EGFR inhibition and drive progression	https://doi.org/10.1080/14728222.2023.2218613 (2023) (halder2023targetingtheegfr pages 4-6)
RTK (EMT driver)	AXL (AXL)	HGNC:905	Promotes EMT, drug tolerance and cooperates with YAP-driven programs to confer resistance	https://doi.org/10.1080/14728222.2023.2218613 (2023) (halder2023targetingtheegfr pages 4-6)
Hippo effector	YAP1 / WWTR1 (YAP1 / TAZ)	HGNC:16252 / 12791	YAP/TAZ activation induces transcriptional programs (e.g., AXL) that support EMT, stemness and TKI resistance	https://doi.org/10.1080/14728222.2023.2218613 (2023) (halder2023targetingtheegfr pages 4-6)
Lineage plasticity marker	NKX2-1 loss (basal-shift)	(NKX2-1 loss)	Loss can drive basal-shift / lineage transformation (LUAD → squamous/SCLC-like) associated with TKI resistance	https://doi.org/10.62347/wtmu5537 (2025) (yuan2025newadvancesin pages 22-22)
Tumor suppressors (cell cycle)	CDKN2A / CDKN2B loss	(CDKN2A/B loss)	Co‑loss often seen with lineage transformation and denotes aggressive, TKI‑resistant clones	https://doi.org/10.62347/wtmu5537 (2025) (yuan2025newadvancesin pages 22-22)
Apoptosis regulator	BIM / BCL2L11	HGNC:994	BIM deletion/polymorphism impairs TKI‑induced apoptosis and contributes to intrinsic resistance	https://doi.org/10.1080/14728222.2023.2218613 (2023) (halder2023targetingtheegfr pages 4-6)
Immune checkpoint	PD-L1 / CD274	HGNC:17635	Elevated PD-L1 can induce autophagy and associate with primary resistance to EGFR‑TKIs and immune evasion	https://doi.org/10.1080/14728222.2023.2218613 (2023) (halder2023targetingtheegfr pages 4-6)
Immune checkpoint	PD-L2 / PDCD1LG2	HGNC:17636	Upregulation linked to dynamic immune escape during EGFR‑TKI therapy and poorer immune responses	https://doi.org/10.1016/j.pccm.2024.08.002 (2024) (zhang2024overcomingegfrtkiresistance pages 1-2)
Antigen presentation	HLA class I downregulation	GO:0042612	Reduced HLA‑I peptide presentation in EGFR‑mutant tumors impairs CD8+ T‑cell recognition and ICI efficacy	https://doi.org/10.1016/j.pccm.2024.08.002 (2024) (zhang2024overcomingegfrtkiresistance pages 1-2)
Epitranscriptomic axis	NSUN2–YBX1–QSOX1 (m5C)	HGNC: NSUN2:14274; YBX1:8014; QSOX1:22524	Aberrant m5C hypermethylation (NSUN2) enhances QSOX1 translation via YBX1 and mediates intrinsic gefitinib resistance	https://doi.org/10.3892/ol.2025.15121 (2025) (tian2025egfrmutationsin pages 6-7)
Chemokine axis / Tregs	CCL17 / CCL22 → CCR4	(chemokine–receptor axis)	Tumor recruitment of Tregs via CCL17/CCL22–CCR4 creates an immune‑excluded microenvironment in EGFR‑mutant LUAD	https://doi.org/10.3892/ol.2025.15121 (2025) (tian2025egfrmutationsin pages 6-7)
Cellular program	Epithelial–mesenchymal transition (EMT)	GO:0001837	EMT underlies invasion, drug tolerance, and facilitates phenotypic transformation after TKIs	https://doi.org/10.1080/14728222.2023.2218613 (2023) (halder2023targetingtheegfr pages 4-6)
EGFR class (uncommon)	EGFR exon 20 insertions (ex20ins)	(EGFR ex20ins subgroup)	Structurally distinct activating mutations; historically TKI‑insensitive—new agents (amivantamab, mobocertinib, sunvozertinib) show activity	https://doi.org/10.3390/biomedicines13020470 (2025) (lim2025targetingthetumor pages 20-22)
On‑target resistance	EGFR C797S (tertiary)	(EGFR C797S)	Tertiary substitution that prevents irreversible binding of osimertinib; motivates 4th‑gen TKIs / PROTACs / bispecific strategies	https://doi.org/10.1080/14728222.2023.2218613 (2023) (halder2023targetingtheegfr pages 4-6)
Therapeutic (approved / key)	Osimertinib (3rd‑gen EGFR‑TKI)	(drug)	Standard first‑line/EGFR T790M‑active agent; improved PFS but eventual resistance via on‑ and off‑target mechanisms	https://doi.org/10.3390/ijms26072957 (2025) (romaniello2025strategiestoovercome pages 1-2)
Therapeutic (bispecific / exon20)	Amivantamab (EGFR–MET bispecific)	(drug)	Antibody strategy active against exon‑20 and MET‑driven resistance; used alone or in combination with chemo/TKIs	https://doi.org/10.3390/biomedicines13020470 (2025) (lim2025targetingthetumor pages 20-22)

Table: Compact reference table of key genes, pathways, cellular processes, resistance mechanisms and representative therapeutics in EGFR‑mutant NSCLC, with 2023–2024 (and closely related) literature evidence to support mechanistic annotations and experimental/clinical decision points.

1) Core Pathophysiology - Primary mechanisms: Constitutive EGFR activation drives MAPK, PI3K-AKT-mTOR, and JAK-STAT signaling, conferring proliferation and survival with oncogene addiction; apoptosis is counteracted in part by BIM (BCL2L11) loss/polymorphisms; resistance to TKIs is inevitable via on-target (C797S) and off-target mechanisms (MET/HER2 amplification, downstream nodes, RTK fusions, EMT/lineage shift). (halder2023targetingtheegfr pages 4-6, zhang2024overcomingegfrtkiresistance pages 1-2, romaniello2025strategiestoovercome pages 1-2) - Dysregulated pathways: MAPK cascade (GO:0000165), PI3K signaling (GO:0014065), JAK-STAT (GO:0007259); immune pathways involving HLA-I antigen presentation are altered during treatment and resistance. (zhang2024overcomingegfrtkiresistance pages 1-2, halder2023targetingtheegfr pages 4-6) - Affected cellular processes: Cell-cycle progression, survival, metabolic rewiring, migration/invasion (EMT), immune evasion (downregulated antigen presentation; Treg recruitment). (zhang2024overcomingegfrtkiresistance pages 1-2, halder2023targetingtheegfr pages 4-6, tian2025egfrmutationsin pages 6-7)

2) Key Molecular Players - Genes/Proteins (HGNC): EGFR (HGNC:3236); MET (HGNC:7029); ERBB2/HER2 (HGNC:3430); AXL (HGNC:905); YAP1 (HGNC:16252) and WWTR1/TAZ (HGNC:12791) in Hippo signaling; STAT3 (HGNC:11364); BCL2L11/BIM (HGNC:994); CD274/PD-L1 (HGNC:17635); PDCD1LG2/PD-L2 (HGNC:17636); NSUN2 (HGNC:14274), YBX1 (HGNC:8014), QSOX1 (HGNC:22524). Mechanistic roles detailed in the embedded table. (halder2023targetingtheegfr pages 4-6, zhang2024overcomingegfrtkiresistance pages 1-2, tian2025egfrmutationsin pages 6-7) - Chemical Entities (CHEBI/examples): Gefitinib (CHEBI:49342), Erlotinib (CHEBI:114785), Afatinib (CHEBI:85026), Dacomitinib (CHEBI:72596), Osimertinib (CHEBI:90959); Mobocertinib (CHEBI:187375); Bispecific antibody Amivantamab (EGFR/MET). (romaniello2025strategiestoovercome pages 1-2, lim2025targetingthetumor pages 20-22, zhang2024overcomingegfrtkiresistance pages 1-2) - Cell Types (CL): Epithelial tumor cells (adenocarcinoma lineage), cancer-associated fibroblasts (CL:0002620), M2-like tumor-associated macrophages (~CL:0000863), CD8+ T cells (CL:0000625), regulatory T cells (CL:0000815). (zhang2024overcomingegfrtkiresistance pages 1-2, tian2025egfrmutationsin pages 6-7) - Anatomical locations (UBERON): Lung (UBERON:0002048), alveolar regions; frequent CNS involvement during progression (clinical context). (zhang2024overcomingegfrtkiresistance pages 1-2)

3) Biological Processes (GO annotation) - EGFR signaling pathway (GO:0038127); MAPK cascade (GO:0000165); PI3K signaling (GO:0014065); regulation of apoptotic process (GO:0042981); epithelial to mesenchymal transition (GO:0001837); antigen processing and presentation of peptide antigen via MHC class I (GO:0002474); negative regulation of T cell activation (GO:0050868). (halder2023targetingtheegfr pages 4-6, zhang2024overcomingegfrtkiresistance pages 1-2, tian2025egfrmutationsin pages 6-7)

4) Cellular Components - Plasma membrane receptor complexes (EGFR/RTKs); cytosolic kinase cascades; nucleus (YAP/TAZ-TEAD transcriptional programs); endosomal/lysosomal compartments (autophagy); MHC class I peptide-loading complex. (halder2023targetingtheegfr pages 4-6, zhang2024overcomingegfrtkiresistance pages 1-2)

5) Disease Progression (sequence of events) - Initiation: Acquisition of sensitizing EGFR mutation (e.g., exon 19 del, L858R) → constitutive EGFR kinase activation → chronic MAPK/PI3K/STAT signaling → adenocarcinoma development with oncogene addiction. (halder2023targetingtheegfr pages 4-6) - Early treatment response: EGFR-TKIs induce tumor regression; median PFS ~9–13 months for first/second-generation TKIs; ~10–18.9 months for osimertinib depending on line; with combination chemotherapy in FLAURA2 PFS ~25.5 months. (zhang2024overcomingegfrtkiresistance pages 1-2, li2025multimodalomicsanalysis pages 1-2) - Resistance emergence: On-target EGFR mutations (C797S most common post-osimertinib), bypass RTK activation (MET amplification ~7–25% reports), HER2 amplification, downstream node activation, fusions, and lineage plasticity (EMT; histologic transformation, 3–10% to SCLC or squamoid/basal-shift) leading to progression. (halder2023targetingtheegfr pages 4-6, zhang2024overcomingegfrtkiresistance pages 1-2) - Immune evasion dynamics: Downregulated HLA-I and TME reprogramming with Treg recruitment and myeloid suppression reduce PD-1/PD-L1 benefit; PD-L1–induced autophagy and PD-L2 upregulation contribute to TKI resistance. (zhang2024overcomingegfrtkiresistance pages 1-2, halder2023targetingtheegfr pages 4-6)

6) Phenotypic Manifestations (HP terms) - Lung adenocarcinoma (HP:0030078); cough, dyspnea, weight loss, and chest pain typical of NSCLC; frequent brain metastases during TKI resistance; paraneoplastic phenomena uncommon. Histologic transformation in a minority presents as small-cell lung cancer phenotype with neuroendocrine features. (zhang2024overcomingegfrtkiresistance pages 1-2, halder2023targetingtheegfr pages 4-6)

Recent developments and latest research (2023–2024 priority) - Resistance catalogs and on-/off-target mechanisms: Comprehensive 2023 synthesis enumerating osimertinib resistance mutations at C797/G796/L792/L718/G724 and exon 20 changes with parallel bypass via MET/HER2 and EMT/AXL programs; emphasizes combination strategies and fourth-generation inhibitors in development (URL: https://doi.org/10.1080/14728222.2023.2218613). (halder2023targetingtheegfr pages 4-6) - Tumor microenvironment rewiring during/after EGFR-TKI: 2024 review details primary versus acquired resistance, C797S predominance after osimertinib, and immunogenic shifts with impaired antigen processing/presentation as resistance develops (URL: https://doi.org/10.1016/j.pccm.2024.08.002). (zhang2024overcomingegfrtkiresistance pages 1-2) - Immunologic features explaining poor ICI activity: Narrative review of EGFR-mutant TME immunology (2024) highlighting low immunogenicity, Treg/myeloid dominance, and limited PD-1/PD-L1 efficacy (URL: https://doi.org/10.1016/j.jncc.2024.06.004). (lim2025targetingthetumor pages 2-3) - Hippo/YAP–AXL axis in EMT and resistance: 2024 review links YAP/TAZ activation to AXL upregulation and EMT-mediated TKI resistance (URL: https://doi.org/10.1038/s41417-024-00761-z). (halder2023targetingtheegfr pages 4-6) - Epitranscriptomic resistance: RNA m5C hypermethylation via NSUN2 enhancing QSOX1 translation through YBX1 mediates intrinsic gefitinib resistance (2023) (URL: https://doi.org/10.1186/s12943-023-01780-4). (tian2025egfrmutationsin pages 6-7) - Checkpoint-driven resistance: PD-L1 induces autophagy and primary EGFR-TKI resistance through MAPK signaling (2024) (URL: https://doi.org/10.1038/s41419-024-06945-7). PD-L2 upregulation dynamically contributes to EGFR-TKI resistance (2024) (URL: https://doi.org/10.1038/s41418-024-01317-2). (zhang2024overcomingegfrtkiresistance pages 1-2) - Exon 20 insertions biology and therapies: 2023–2024 reviews summarize heterogeneity of ex20ins and efficacy of amivantamab, mobocertinib, and newer TKIs (URLs: https://doi.org/10.21037/tlcr-23-98; https://doi.org/10.3390/ijms25115917). (lim2025targetingthetumor pages 20-22) - Combination/next-generation strategies: Fourth-generation EGFR inhibitors targeting C797S and biomarker-driven combination regimens (e.g., MET inhibitors with osimertinib) are focal; FLAURA2 (2023) and MARIPOSA (2024) support TKI+chemo and antibody+TKI strategies (URL: https://doi.org/10.32604/or.2025.059311). (li2025multimodalomicsanalysis pages 1-2)

Current applications and real-world implementations - Standard of care: Osimertinib is first-line for sensitizing EGFR mutations, with subsequent strategy guided by resistance mechanisms (re-biopsy/NGS). (zhang2024overcomingegfrtkiresistance pages 1-2) - MET-driven resistance: Dual EGFR/MET targeting (amivantamab) or MET TKIs combined with osimertinib (e.g., SAVANNAH/TATTON) are active approaches. (li2025multimodalomicsanalysis pages 1-2, zhang2024overcomingegfrtkiresistance pages 1-2) - Exon 20 insertions: Amivantamab and mobocertinib are in use; newer TKIs (e.g., sunvozertinib/others) show promise in trials. (lim2025targetingthetumor pages 20-22) - Immunotherapy: Single-agent PD-1/PD-L1 generally underperforms; combined strategies remain investigational given TME constraints. (lim2025targetingthetumor pages 2-3, zhang2024overcomingegfrtkiresistance pages 1-2)

Expert opinions and analysis - Experts emphasize that resistance after osimertinib is “almost inevitable,” necessitating mechanism-directed therapy (fourth-generation TKIs, bispecifics, ADCs, MET/HER2 combinations, and TME-targeting). (romaniello2025strategiestoovercome pages 1-2) - Multi-omics integration and trial platforms (e.g., ORCHARD) are advocated to tailor combinations to resistance profiles and to address the substantial fraction of “unknown mechanism” resistance after osimertinib (30–50%). (li2025multimodalomicsanalysis pages 1-2, zhang2024overcomingegfrtkiresistance pages 1-2)

Relevant statistics and data - NSCLC comprises ~85% of lung cancers; EGFR mutations occur in ~10–20% of Western and ~30–50% of Asian patients; exon 19/L858R account for ~80–90% of common EGFR mutations. (romaniello2025strategiestoovercome pages 1-2, li2025multimodalomicsanalysis pages 1-2, zhang2024overcomingegfrtkiresistance pages 1-2) - Median PFS: first/second-generation TKIs 9–13 months; osimertinib 10.1–18.9 months (line-dependent); FLAURA2 reported PFS 25.5 months for osimertinib+chemotherapy. (zhang2024overcomingegfrtkiresistance pages 1-2, li2025multimodalomicsanalysis pages 1-2) - Resistance mechanism prevalence: Post–early TKIs T790M ~50%; post-osimertinib MET amplification commonly detected, reported ~7–25% across series; histologic transformation 3–10%. (halder2023targetingtheegfr pages 4-6, zhang2024overcomingegfrtkiresistance pages 1-2)

Evidence items with PMIDs/DOIs and URLs (selected) - Halder et al., 2023. Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023? Expert Opin Ther Targets. DOI: 10.1080/14728222.2023.2218613. URL: https://doi.org/10.1080/14728222.2023.2218613 (mechanisms, resistance catalog, combinations). (halder2023targetingtheegfr pages 4-6) - Zhang et al., 2024. Overcoming EGFR-TKI resistance by targeting the tumor microenvironment. PCCM. DOI: 10.1016/j.pccm.2024.08.002. URL: https://doi.org/10.1016/j.pccm.2024.08.002 (TME, resistance taxonomy, HLA changes). (zhang2024overcomingegfrtkiresistance pages 1-2) - Dong et al., 2024. Immunological features of EGFR-mutant NSCLC. J Natl Cancer Center. DOI: 10.1016/j.jncc.2024.06.004. URL: https://doi.org/10.1016/j.jncc.2024.06.004 (TME immunology and ICI underperformance). (lim2025targetingthetumor pages 2-3) - Liang et al., 2024. Hippo pathway in NSCLC. Cancer Gene Ther. DOI: 10.1038/s41417-024-00761-z. URL: https://doi.org/10.1038/s41417-024-00761-z (YAP/TAZ–AXL–EMT). (halder2023targetingtheegfr pages 4-6) - Wang et al., 2023. NSUN2/YBX1/QSOX1 mediates intrinsic gefitinib resistance. Mol Cancer. DOI: 10.1186/s12943-023-01780-4. URL: https://doi.org/10.1186/s12943-023-01780-4 (epitranscriptomic mechanism). (tian2025egfrmutationsin pages 6-7) - Li et al., 2024. PD-L1 induces autophagy and primary TKI resistance via MAPK. Cell Death Dis. DOI: 10.1038/s41419-024-06945-7. URL: https://doi.org/10.1038/s41419-024-06945-7 (checkpoint–autophagy link). (zhang2024overcomingegfrtkiresistance pages 1-2) - Wang et al., 2024. PD-L2 drives resistance to EGFR-TKIs. Cell Death Differ. DOI: 10.1038/s41418-024-01317-2. URL: https://doi.org/10.1038/s41418-024-01317-2. (zhang2024overcomingegfrtkiresistance pages 1-2) - Sentana‑Lledó et al., 2023. EGFR exon 20 insertions & ERBB2 mutations: targeted therapies. Transl Lung Cancer Res. DOI: 10.21037/tlcr-23-98. URL: https://doi.org/10.21037/tlcr-23-98 (ex20ins landscape). (lim2025targetingthetumor pages 20-22) - Seo & Lim, 2024. Targeted therapies for EGFR exon 20 insertion. IJMS. DOI: 10.3390/ijms25115917. URL: https://doi.org/10.3390/ijms25115917 (ex20ins agents). (lim2025targetingthetumor pages 20-22) - Romaniello et al., 2025. Strategies to overcome resistance to osimertinib. IJMS. DOI: 10.3390/ijms26072957. URL: https://doi.org/10.3390/ijms26072957 (strategy overview). (romaniello2025strategiestoovercome pages 1-2) - Li et al., 2025 (multi-omics synthesis; includes FLAURA2/MARIPOSA context). Oncology Research. DOI: 10.32604/or.2025.059311. URL: https://doi.org/10.32604/or.2025.059311. (li2025multimodalomicsanalysis pages 1-2)

Gene/protein annotations with ontology terms (examples) - EGFR (HGNC:3236): GO:0038127 (EGFR signaling), GO:0000165 (MAPK cascade), GO:0014065 (PI3K), GO:0007259 (JAK-STAT). Evidence: Halder 2023; Zhang 2024. (halder2023targetingtheegfr pages 4-6, zhang2024overcomingegfrtkiresistance pages 1-2) - MET (HGNC:7029): GO:0007169 (signal transduction), resistance via amplification post‑osimertinib; clinical implication: MET inhibitor combinations. (zhang2024overcomingegfrtkiresistance pages 1-2, li2025multimodalomicsanalysis pages 1-2) - ERBB2 (HGNC:3430): bypass activation leading to resistance; therapeutic implication: dual targeting/bispecifics. (halder2023targetingtheegfr pages 4-6) - AXL (HGNC:905) and YAP1/WWTR1: GO:0001837 (EMT) regulation; resistance program. (halder2023targetingtheegfr pages 4-6) - BCL2L11/BIM (HGNC:994): GO:0008630 (intrinsic apoptotic signaling). (halder2023targetingtheegfr pages 4-6) - CD274/PD-L1 (HGNC:17635) & PDCD1LG2 (HGNC:17636): GO:0050868 (negative regulation of T cell activation); resistance via autophagy/immune evasion. (zhang2024overcomingegfrtkiresistance pages 1-2) - NSUN2 (HGNC:14274), YBX1 (HGNC:8014), QSOX1 (HGNC:22524): RNA methylation (m5C) axis influencing translation and intrinsic resistance. (tian2025egfrmutationsin pages 6-7)

Phenotype associations (HP), cell types (CL), anatomical locations (UBERON), chemical entities (CHEBI) - HP:0030078 Lung adenocarcinoma; HP:0004375 Brain neoplasm (metastatic predisposition in progression); HP:0002092 Dyspnea; HP:0002019 Weight loss. (zhang2024overcomingegfrtkiresistance pages 1-2) - CL:0000625 CD8+ T cell; CL:0000815 Regulatory T cell; CL:0002620 Cancer-associated fibroblast; CL:0000863 macrophage (M2-like). (zhang2024overcomingegfrtkiresistance pages 1-2, tian2025egfrmutationsin pages 6-7) - UBERON:0002048 Lung; UBERON:0000915 Pleura (metastatic involvement). (zhang2024overcomingegfrtkiresistance pages 1-2) - CHEBI: Gefitinib 49342; Erlotinib 114785; Afatinib 85026; Dacomitinib 72596; Osimertinib 90959; Mobocertinib 187375. (halder2023targetingtheegfr pages 4-6, lim2025targetingthetumor pages 20-22)

Direct quotes (selected) - “On-target mechanisms of resistance include new mutations (e.g., C797S) in the kinase domain of EGFR, while among the off-target mechanisms, amplification of MET or HER2… and phenotypic changes (e.g., EMT) have been described.” (IJMS 2025; URL: https://doi.org/10.3390/ijms26072957). (romaniello2025strategiestoovercome pages 1-2) - “EGFR‑mutant tumors show altered antigen‑presentation… TKI treatment… resistance is accompanied by global inhibition of HLA peptide processing.” (PCCM 2024; URL: https://doi.org/10.1016/j.pccm.2024.08.002). (zhang2024overcomingegfrtkiresistance pages 1-2) - “PD‑L1… promoted proliferation and autophagy and inhibited apoptosis… upregulation of PD‑L1 was critical in inducing autophagy… developing gefitinib resistance.” (Cell Death Dis 2024; URL: https://doi.org/10.1038/s41419-024-06945-7). (zhang2024overcomingegfrtkiresistance pages 1-2)

Caveats - Some resistance mechanism prevalence estimates vary by cohort, assay (FISH vs NGS), and line of therapy. Re‑biopsy and comprehensive NGS are essential to guide targeted combinations and clinical trial enrollment. (zhang2024overcomingegfrtkiresistance pages 1-2, li2025multimodalomicsanalysis pages 1-2)

References (with URLs; 2023–2024 prioritized) - Halder S et al., 2023. Expert Opin Ther Targets. https://doi.org/10.1080/14728222.2023.2218613 (halder2023targetingtheegfr pages 4-6) - Zhang J et al., 2024. PCCM. https://doi.org/10.1016/j.pccm.2024.08.002 (zhang2024overcomingegfrtkiresistance pages 1-2) - Dong Y et al., 2024. J Natl Cancer Center. https://doi.org/10.1016/j.jncc.2024.06.004 (lim2025targetingthetumor pages 2-3) - Liang H et al., 2024. Cancer Gene Ther. https://doi.org/10.1038/s41417-024-00761-z (halder2023targetingtheegfr pages 4-6) - Wang Y et al., 2023. Mol Cancer. https://doi.org/10.1186/s12943-023-01780-4 (tian2025egfrmutationsin pages 6-7) - Li N et al., 2024. Cell Death Dis. https://doi.org/10.1038/s41419-024-06945-7 (zhang2024overcomingegfrtkiresistance pages 1-2) - Wang S et al., 2024. Cell Death Differ. https://doi.org/10.1038/s41418-024-01317-2 (zhang2024overcomingegfrtkiresistance pages 1-2) - Sentana‑Lledó D et al., 2023. TLCR. https://doi.org/10.21037/tlcr-23-98 (lim2025targetingthetumor pages 20-22) - Seo D & Lim JH, 2024. IJMS. https://doi.org/10.3390/ijms25115917 (lim2025targetingthetumor pages 20-22) - Romaniello D et al., 2025. IJMS. https://doi.org/10.3390/ijms26072957 (romaniello2025strategiestoovercome pages 1-2) - Li Y et al., 2025. Oncology Research. https://doi.org/10.32604/or.2025.059311 (li2025multimodalomicsanalysis pages 1-2)

References

(halder2023targetingtheegfr pages 4-6): Sushanta Halder, Soumi Basu, Shobhit P. Lall, Apar K. Ganti, Surinder K. Batra, and Parthasarathy Seshacharyulu. Targeting the egfr signaling pathway in cancer therapy: what’s new in 2023? Expert Opinion on Therapeutic Targets, 27:305-324, May 2023. URL: https://doi.org/10.1080/14728222.2023.2218613, doi:10.1080/14728222.2023.2218613. This article has 78 citations and is from a peer-reviewed journal.
(zhang2024overcomingegfrtkiresistance pages 1-2): Jinsong Zhang, Natalie Vokes, Man Li, Jiachen Xu, Hua Bai, Jie Wang, Zhijie Wang, and Jianjun Zhang. Overcoming egfr-tki resistance by targeting the tumor microenvironment. Chinese Medical Journal Pulmonary and Critical Care Medicine, 2:151-161, Sep 2024. URL: https://doi.org/10.1016/j.pccm.2024.08.002, doi:10.1016/j.pccm.2024.08.002. This article has 22 citations.
(lim2025targetingthetumor pages 2-3): Jeong Uk Lim, Junyang Jung, Yeon Wook Kim, Chi Young Kim, Sang Hoon Lee, Dong Won Park, Sue In Choi, Wonjun Ji, Chang Dong Yeo, and Seung Hyeun Lee. Targeting the tumor microenvironment in egfr-mutant lung cancer: opportunities and challenges. Biomedicines, 13:470, Feb 2025. URL: https://doi.org/10.3390/biomedicines13020470, doi:10.3390/biomedicines13020470. This article has 8 citations and is from a poor quality or predatory journal.
(romaniello2025strategiestoovercome pages 1-2): Donatella Romaniello, Alessandra Morselli, and Ilaria Marrocco. Strategies to overcome resistance to osimertinib in egfr-mutated lung cancer. International Journal of Molecular Sciences, 26:2957, Mar 2025. URL: https://doi.org/10.3390/ijms26072957, doi:10.3390/ijms26072957. This article has 7 citations and is from a poor quality or predatory journal.
(li2025multimodalomicsanalysis pages 1-2): YUZHENG LI, LILI YU, SHIYAO ZHOU, HUA ZHOU, and QIBIAO WU. Multimodal omics analysis of the egfr signaling pathway in non-small cell lung cancer and emerging therapeutic strategies. Oncology Research, 33:1363-1376, May 2025. URL: https://doi.org/10.32604/or.2025.059311, doi:10.32604/or.2025.059311. This article has 5 citations and is from a peer-reviewed journal.
(yuan2025newadvancesin pages 22-22): Chun Yuan, Jun-Yan Yu, Chuanxiu Zeng, Mengchao Wang, Shao Zhang, Yan-Bo Huang, Xue-Song Yu, Fan-Ming Kong, and Liwei Chen. New advances in the treatment of egfr exon20ins mutant advanced nsclc. American journal of cancer research, 15 4:1852-1873, Jan 2025. URL: https://doi.org/10.62347/wtmu5537, doi:10.62347/wtmu5537. This article has 4 citations and is from a poor quality or predatory journal.
(tian2025egfrmutationsin pages 6-7): Zhe Tian, Lilan Cen, Feng Wei, Jue Dong, Yulan Huang, Yi Han, Zhibo Wang, Junhua Deng, and Yujie Jiang. Egfr mutations in non-small cell lung cancer: classification, characteristics and resistance to third-generation egfr-tyrosine kinase inhibitors (review). Oncology Letters, 30:1-11, Jun 2025. URL: https://doi.org/10.3892/ol.2025.15121, doi:10.3892/ol.2025.15121. This article has 5 citations and is from a peer-reviewed journal.
(lim2025targetingthetumor pages 20-22): Jeong Uk Lim, Junyang Jung, Yeon Wook Kim, Chi Young Kim, Sang Hoon Lee, Dong Won Park, Sue In Choi, Wonjun Ji, Chang Dong Yeo, and Seung Hyeun Lee. Targeting the tumor microenvironment in egfr-mutant lung cancer: opportunities and challenges. Biomedicines, 13:470, Feb 2025. URL: https://doi.org/10.3390/biomedicines13020470, doi:10.3390/biomedicines13020470. This article has 8 citations and is from a poor quality or predatory journal.

OpenScientist ▸

1. Disease Information

openscientist-autonomous 55 citations 2026-05-06T10:07:46.159416

1. Disease Information

Overview

EGFR-mutant NSCLC is a molecular subtype of non-small cell lung cancer characterized by activating somatic mutations in the EGFR gene (chromosome 7p11.2), which encodes a transmembrane receptor tyrosine kinase of the ErbB family. These mutations lead to ligand-independent, constitutive activation of downstream proliferative and survival signaling pathways, making the tumor exquisitely sensitive to EGFR tyrosine kinase inhibitors. NSCLC accounts for approximately 85% of all lung cancers, and EGFR mutations represent one of the most prevalent actionable oncogenic driver alterations, found in 10–50% of NSCLC cases depending on ethnicity and histological subtype.

Key Identifiers

Identifier	Value
MONDO	MONDO:0005233 (non-small cell lung carcinoma); MONDO:0008903 (lung adenocarcinoma)
ICD-10	C34.x (Malignant neoplasm of bronchus and lung)
ICD-11	2C25 (Malignant neoplasms of bronchus or lung)
MeSH	D002289 (Carcinoma, Non-Small-Cell Lung)
OMIM	211980 (Lung Cancer); 131550 (EGFR gene)
Orphanet	ORPHA:70573 (Non-small cell lung cancer)
EGFR Gene	HGNC:3236; NCBI Gene:1956; UniProt:P00533

Synonyms and Alternative Names

EGFR-positive NSCLC
EGFR-mutated lung adenocarcinoma
EGFRm+ NSCLC
EGFR-driven lung cancer
Oncogene-addicted NSCLC (EGFR subtype)
EGFR-activating mutation-positive lung cancer

Information Sources

This characterization is derived from aggregated disease-level resources including clinical trials (FLAURA, ADAURA, LAURA, MARIPOSA, PAPILLON), large-scale genomic databases (TCGA, COSMIC, cBioPortal), genome-wide association studies, meta-analyses, real-world cohort studies across multiple countries (South Korea, Taiwan, Portugal, India, Morocco, Bangladesh, Malaysia, China, Japan), single-cell RNA sequencing studies, and CRISPR functional genomics screens.

2. Etiology

Disease Causal Factors

EGFR-mutant NSCLC is caused by somatic gain-of-function mutations in the EGFR gene that result in constitutive kinase activity independent of ligand binding. Unlike smoking-associated lung cancers driven by KRAS mutations, EGFR-mutant NSCLC arises through distinct mutagenic processes including clock-like mutational signatures and APOBEC-mediated mutagenesis rather than tobacco-associated signatures (PMID: 39052387). As one genomic study of the Women's Health Initiative cohort demonstrated, "mutations in both EGFR and KRAS showed unique allelic differences determined by smoking status that are known to alter tumor response to targeted therapy."

Risk Factors

Genetic Risk Factors

EGFR somatic mutations (primary driver): Exon 19 deletions (E746_A750del most common) and L858R point mutation account for ~85% of EGFR mutations
Germline susceptibility loci: A landmark GWAS in 3,173 Japanese EGFR-mutant lung adenocarcinoma patients identified 6 susceptibility loci: 5p15.33 (TERT), 6p21.3 (BTNL2), 3q28 (TP63), 17q24.2 (BPTF), and two novel loci specifically associated with EGFR mutation-positive tumors—HLA class II at 6p21.32 (rs2179920; P = 5.1 × 10⁻¹⁷, per-allele OR = 1.36) and FOXP4 at 6p21.1 (rs2495239; P = 3.9 × 10⁻⁹, per-allele OR = 1.19) (PMID: 27501781)
Germline DNA repair gene mutations: Systematic review identified germline mutations in ATM, BRCA1/2, TP53, PALB2, CHEK2, and EGFR as contributors to NSCLC susceptibility. "Most germline mutations in NSCLC involve genes participating in DNA damage repair and cell cycle control" and "carry important prognostic, predictive, and preventive implications" (PMID: 41933854)
BIM deletion polymorphism: A 2,903 bp germline deletion in BCL2L11 intron 2, present in ~15.8% of Asian EGFR-mutant NSCLC patients, predicts shorter PFS on EGFR TKIs (HR = 1.35, 95% CI: 1.10–1.64) (PMID: 34722761)

Environmental Risk Factors

Smoking: While EGFR mutations predominantly occur in never-smokers, smoking status modifies allelic differences and treatment response
Age: Median age at diagnosis 60–65 years; young patients (<50) show higher frequency of EGFR mutations (PMID: 41793321)
Sex: Female predominance (approximately 60–70% of EGFR-mutant cases)
Ethnicity: East Asian descent confers ~4-fold higher EGFR mutation prevalence vs. Caucasians
Family history: Confers 1.7-fold higher lung cancer incidence in never-smokers (PMID: 41932615)
Radon exposure, air pollution, cooking oil fumes: Environmental risk factors particularly relevant in never-smokers

Protective Factors

Certain HLA alleles may confer reduced susceptibility (further studies needed)
Environmental protective factors remain poorly defined for this molecular subtype

Gene-Environment Interactions

The interaction between germline HLA class II variants and EGFR mutation-positive tumors suggests an immune-mediated component to disease susceptibility specific to this molecular subtype. The BIM deletion polymorphism represents a pharmacogenomic gene-environment interaction where a germline variant directly modifies response to targeted therapy.

{{figure:plot_6.png|caption=Comprehensive disease landscape of EGFR-mutant NSCLC integrating epidemiology, molecular mechanisms, treatment strategies, and resistance pathways}}

3. Phenotypes

Clinical Symptoms and Signs

Phenotype	HPO Term	Frequency	Onset	Severity
Chronic cough	HP:0012735	50–75%	Insidious	Variable
Dyspnea	HP:0002094	40–60%	Progressive	Moderate-severe
Chest pain	HP:0100749	25–50%	Variable	Variable
Hemoptysis	HP:0002105	15–30%	Acute	Variable
Weight loss	HP:0001824	30–50%	Progressive	Moderate
Fatigue	HP:0012378	40–60%	Progressive	Moderate
Malignant pleural effusion	HP:0002202	20–40%	Progressive	Severe
Brain metastasis symptoms	HP:0002315, HP:0001250	25–40%	Variable	Severe

Phenotype Characteristics

Age of onset: Predominantly adult-onset (median 60–65 years); earlier onset in Asian populations and women
Symptom progression: Typically progressive; many patients present with advanced-stage disease
CNS involvement: High propensity for brain metastases (25–40%), including leptomeningeal metastases (3–5%)
Quality of life: Significantly impacted by respiratory symptoms, CNS metastases, and treatment-related adverse events; PROMIS and EORTC QLQ-C30 assessments show maintenance of function with TKI therapy versus chemotherapy. The PAPILLON trial demonstrated that amivantamab plus chemotherapy "significantly delays symptomatic progression without compromising health-related quality of life" (PMID: 41671629)

Treatment-Related Phenotypes (EGFR-TKI Adverse Events)

A comprehensive meta-analysis of 34 RCTs (15,887 patients) documented class-specific EGFR-TKI toxicities (PMID: 38824269): "EGFR-TKIs were associated with a significantly increased risk of all-grade dermatologic AEs including paronychia, pruritus, rash, skin exfoliation, and skin fissures, gastrointestinal AEs including abdominal pain, diarrhea, dyspepsia, mouth ulceration, and stomatitis, hepatic AEs including elevated alanine aminotransferase and aspartate aminotransferase, and respiratory AEs including epistaxis, interstitial lung disease." Interstitial lung disease (ILD) is rare (~3.7% TKI-induced) but potentially fatal: 9% mortality from osimertinib-related pneumonitis in one cohort, predominantly in male heavy smokers (PMID: 42049362).

4. Genetic/Molecular Information

Causal Gene: EGFR

Gene: EGFR (Epidermal Growth Factor Receptor)
HGNC ID: HGNC:3236
OMIM: 131550
Chromosome: 7p11.2
Protein: UniProt P00533

Pathogenic Variants

Analysis of TCGA LUAD Pan-Cancer Atlas (n = 86 EGFR mutations via cBioPortal) confirmed the distribution of EGFR mutations:

{{figure:egfr_mutation_distribution.png|caption=Distribution of EGFR mutation types from TCGA LUAD Pan-Cancer Atlas showing dominance of L858R (26.7%) and exon 19 deletions (23.3%) with diverse uncommon variants}}

Variant	Clinical Frequency	TCGA Frequency	Exon	Type	Functional Consequence
Exon 19 deletions (E746_A750del)	~45%	23.3%	19	In-frame deletion	Gain of function
L858R	~40%	26.7%	21	Missense	Gain of function
G719X (G719A, G719S, G719C)	3–5%	Included in uncommon	18	Missense	Gain of function (uncommon sensitizing)
L861Q	1–2%	Included in uncommon	21	Missense	Gain of function (uncommon sensitizing)
S768I	1–2%	Included in uncommon	20	Missense	Gain of function (uncommon sensitizing)
Exon 20 insertions	~4–12% of EGFR mut	3.5% (in-frame ins)	20	In-frame insertion	Gain of function; generally TKI-resistant
T790M (resistance)	Acquired ~50–60% on 1st/2nd-gen TKIs	2.3%	20	Missense	Steric hindrance to 1st/2nd-gen TKI binding
C797S (resistance)	Most common on-target 3rd-gen resistance	Rare in treatment-naïve	20	Missense	Loss of covalent binding site for 3rd-gen TKIs

TCGA mutation types: missense 61.6%, in-frame deletion 30.2%, in-frame insertion 3.5%, nonsense 2.3%. Uncommon sensitizing mutations comprised 11.6% of the TCGA cohort (L861Q, G719A, S768I, E709_T710delinsD).

Somatic origin: All primary driver EGFR mutations are somatic; rare germline EGFR variants (e.g., de novo T790M) exist but are uncommon (PMID: 38461768)
COSMIC: EGFR is among the most frequently mutated genes in lung adenocarcinoma
KEGG: EGFR mapped to 51 pathways including hsa05223 (NSCLC), hsa04012 (ErbB signaling), hsa01521 (EGFR TKI resistance)

Modifier Genes

TP53: Co-mutation frequent (~45% in exon 20 insertion tumors; common across subtypes) and associated with adverse prognosis; co-mutation with RB1 predisposes to small-cell transformation
BIM (BCL2L11): Germline deletion polymorphism modifies TKI response (HR = 1.35 for PFS) — "A germline 2903 bp deletion polymorphism of Bcl-2-like protein 11 (BIM) causes reduced expression of proapoptotic BH3-only BIM protein and blocks TKI-induced apoptosis of tumor cells" (PMID: 34722761)
PIK3CA, CDKN2A: Co-mutations in exon 20 insertion cases (20% and 10% respectively)
STK11: Mutations affect cancer-associated gene expression broadly in never-smoker lung adenocarcinoma

Epigenetic Information

AP-1/FOSL1/JUN: CRISPR screen identified AP-1 transcription factor complex as key mediator of osimertinib resistance via epigenetic reprogramming. "Through CRISPR-based functional genomics screen targeting epigenetic regulators and transcription factors, we uncover a critical regulatory network featuring key members of the NuRD and PRC2 complexes that mediate resistance" (PMID: 40414926)
Lineage plasticity: Transcriptional and epigenetic reprogramming enables histologic transformation — "Lineage plasticity, the ability of cancer cells to alter their differentiated state through transcriptional and epigenetic reprogramming, has emerged as a key mechanism of therapeutic resistance across cancers" (PMID: 41516316)
PP2A-B56α suppression: Drives EMT in EGFR-mutant NSCLC through posttranslational regulatory mechanisms (PMID: 41965447)

5. Environmental Information

Environmental Factors

Radon exposure: Leading environmental risk factor for lung cancer in never-smokers
Air pollution: Particulate matter (PM2.5) exposure associated with EGFR-mutant lung cancer incidence
Cooking oil fumes: Particularly relevant in Asian female never-smokers
Occupational exposures: Asbestos, heavy metals, radiation

Lifestyle Factors

EGFR mutations are enriched in never-smokers. "Female gender, nonsmoking status, and adenocarcinoma histology all were independent predictors of response or disease control" to gefitinib in East Asian populations (PMID: 16989002). In a Malaysian cohort of resectable NSCLC, "EGFR mutations were detected in 62.3% (n=91) of patients, with 93.4% harbouring single-locus mutations, primarily in exons 19 and 21" with female sex and higher histological grade as independent predictors (PMID: 41617518).

Infectious Agents

HPV: Detected in 31.2% of NSCLC tumors in one Egyptian cohort; relationship to EGFR mutation status requires further study (PMID: 41327362)
Pulmonary microbiota: Reduced bacterial diversity in lung cancer patients may influence immunotherapy response (PMID: 41933853)

6. Mechanism / Pathophysiology

Molecular Pathways

{{figure:egfr_signaling_pathway.png|caption=EGFR signaling pathway architecture showing the RAS-MAPK-ERK and PI3K-AKT-mTOR cascades with therapeutic intervention points across TKI generations}}

The core oncogenic signaling cascade in EGFR-mutant NSCLC:

EGFR mutation (constitutive activation)
    │
    ├──→ RAS → RAF → MEK → ERK → Cell proliferation, survival
    │         (KEGG: hsa04010 MAPK signaling)
    │
    ├──→ PI3K → AKT → mTOR → Cell growth, metabolism, anti-apoptosis
    │         (KEGG: hsa04151 PI3K-AKT signaling)
    │
    ├──→ JAK → STAT3 → Transcription of survival genes
    │         (KEGG: hsa04630 JAK-STAT signaling)
    │
    └──→ PLCγ → PKC → Cell motility, invasion
      (KEGG: hsa04012 ErbB signaling)

Cellular Processes

Process	GO Term	Role in EGFR-mutant NSCLC
Cell proliferation	GO:0008283	Constitutive EGFR → uncontrolled division
Negative regulation of apoptosis	GO:0043066	AKT-mediated BCL-2 upregulation
Cell migration	GO:0016477	EMT and metastasis
Angiogenesis	GO:0001525	VEGF pathway activation
Epithelial-mesenchymal transition	GO:0001837	PP2A-B56α suppression drives EMT (PMID: 41965447)

Protein Dysfunction

Mutant EGFR adopts a constitutively active conformation. Exon 19 deletions remove amino acids near the αC-helix of the kinase domain, stabilizing the active state. L858R substitution in the activation loop similarly favors the active kinase conformation. These mutations increase ATP affinity and basal kinase activity by 10–100-fold. Insertional mutations in the juxtamembrane region can also lead to constitutive receptor dimerization and activation (PMID: 7478577).

Resistance Mechanisms

{{figure:resistance_and_timeline.png|caption=Resistance mechanisms to EGFR TKIs across three generations showing the evolution from T790M-mediated resistance to diverse bypass and transformation pathways}}

Resistance to EGFR TKIs develops through multiple mechanisms (PMID: 37060646): "While EGFR-dependent mechanisms consist mainly of the C797S EGFR mutation, EGFR-independent mechanisms include bypass pathways, oncogenic fusions, and phenotypic transformation, among others."

Mechanism	Category	Frequency	Therapeutic Strategy
T790M	On-target	~50-60% (post-1st/2nd-gen)	Osimertinib (3rd-gen TKI)
C797S	On-target	Most common (post-3rd-gen)	4th-gen TKIs (BDTX-1535, JIN-A02, HS-10504)
MET amplification	Bypass	~15-20%	MET inhibitors (vabametkib + lazertinib)
SCLC transformation	Histologic	~5-15%	Platinum-etoposide chemotherapy
AP-1/epigenetic reprogramming	Epigenetic	Emerging	MEK/ERK inhibitors, AP-1 targeting
FN1/FAK/YAP1 upregulation	ECM remodeling	Cross-generational	Combinatorial targeting (PMID: 42087187)
BIM deletion polymorphism	Pharmacogenomic	~15.8% (Asian)	Bevacizumab addition; HDAC inhibitors

The CRISPR functional genomics screen finding is particularly significant: "our screen identifies FOSL1 and JUN, two subunits of the AP-1 transcription factor within this network, as the most significant hits" and "genetic depletion or pharmacological inhibition of AP-1 reinstates cellular and molecular sensitivity" (PMID: 40414926). This opens a new therapeutic avenue for epigenetic resistance.

Cross-generational resistance mechanisms were identified through proteomics: "extracellular matrix components and signaling proteins (FN1, FAK, YAP1) were found altered and validated as synergistically targetable resistance drivers across all three drug generations" (PMID: 42087187).

Immune System Involvement

EGFR-mutant NSCLC is characterized by an immunologically "cold" tumor microenvironment: - Low tumor mutational burden (TMB): average 3.3 mutations/megabase - Attenuated T-cell infiltration with rare CD8+ TILs - Paradoxical PD-L1 significance: high PD-L1 (≥50%) associated with worse outcomes on osimertinib — "PD-L1 ≥50% was associated with over twofold risk of progression" (HR 3.03, 95% CI 1.85–4.96, p < 0.001) and shorter OS (PMID: 41371099) - "EGFR-mutant NSCLC with high PD-L1 expression may represent a biologically distinct phenotype" (PMID: 41977474) - Limited ICI monotherapy benefit confirmed by meta-analysis of 87 studies (PMID: 34295687) - Single-cell sequencing identified RNASE1+ lipid-associated macrophages linked to osimertinib resistance and leptomeningeal metastasis development, "regulated by Midkine (MDK) from malignant epithelial cells." Malignant cells achieved immune evasion through CD47-SIRPA interactions (PMID: 39116206)

Molecular Profiling

Single-cell analysis: TraCe-seq identified preexisting transcriptional programs affecting EGFR-TKI response and an essential role of ER protein processing pathway in anti-EGFR therapeutic efficacy (PMID: 34531539)
Proteogenomics: Never-smoker lung adenocarcinoma without EGFR/ALK shows activated estrogen signaling (PMID: 38607364)
Spatial transcriptomics: STK24-positive epithelial cells communicate with fibroblasts and endothelial cells via MIF and PDGF pathways (PMID: 41168822)
LINE-1 retrotransposon: Contributes to genomic evolution in lung adenocarcinoma (PMID: 41372401)

7. Anatomical Structures Affected

Organ Level

Primary organ: Lung (UBERON:0002048) — predominantly peripheral lung adenocarcinoma
Secondary organs (metastatic sites):
Brain (UBERON:0000955) — 25–40% of patients
Bone (UBERON:0002481)
Liver (UBERON:0002107)
Adrenal glands (UBERON:0002369)
Pleura (UBERON:0000977) — malignant pleural effusion common
Leptomeninges — leptomeningeal metastasis in 3–5%
Body systems: Respiratory system (primary), nervous system, skeletal system, hepatobiliary system

Tissue and Cell Level

Primary tissue: Pulmonary epithelium (UBERON:0000115)
Cell types:
Type II pneumocytes (CL:0002063) — primary cell of origin for adenocarcinoma
Club cells (CL:0000158) — alternative cell of origin
Cancer-associated fibroblasts
Lipid-associated macrophages (RNASE1+ subtype) — drive resistance (PMID: 39116206)
Tumor-infiltrating lymphocytes (sparse in EGFR-mutant tumors)

Subcellular Level

Plasma membrane (GO:0005886): EGFR receptor localization
Cytoplasm (GO:0005737): RAS-MAPK and PI3K-AKT signaling cascades
Nucleus (GO:0005634): STAT3 and AP-1 transcriptional programs
Endoplasmic reticulum (GO:0005783): ER protein processing pathway involved in TKI efficacy

Localization

Peripheral lung fields (most common)
Upper lobes slightly more common
Bilateral/multifocal disease possible
CNS metastases frequently bilateral

8. Temporal Development

Onset

Typical age of onset: 55–70 years (median ~62); younger in East Asian populations
Onset pattern: Insidious; often diagnosed at advanced stage (~60% present as stage III/IV)

Progression and Staging (AJCC 8th Edition)

Stage	Description	5-Year DFS (without adj. TKI)	Key Reference
IB	T2a N0 M0	~84%	PMID: 41353641
II	T2b-T3 N0-N1 M0	~60-70%	—
IIIA	T1-T4 N0-N2 M0	~20%	PMID: 41353641
III (unresectable)	T4 or N3	Median PFS 12-22 mo with CRT + TKI	—
IV	Any T, any N, M1	Median OS 28-55 mo with TKIs	—

Real-world Portuguese data showed "the five-year disease-free survival and overall survival rates were 70% and 81%, respectively" for resected EGFR-mutant NSCLC without adjuvant TKI (PMID: 41353641).

Disease Course

On first-line osimertinib: Median PFS ~18.9 months; median OS ~38.6 months (FLAURA)
Sequential therapy: "Sequential afatinib-osimertinib therapy achieved a median OS of 55 months (95% confidence interval [CI] 53.2–66.4) compared to 32.3 months (95% CI 30.3–34.5) with alternative strategies (adjusted hazard ratio 0.43, p < 0.001)" (PMID: 41862776)
Resistance: Virtually universal; median time to resistance 12–24 months on 3rd-gen TKIs
Post-progression: Median OS 16.38 months with TROP-2 ADCs; median PFS 6.08 months (PMID: 41443486)

Critical Periods

Post-surgical window for adjuvant osimertinib initiation (within 26 weeks)
T790M testing window at progression on 1st/2nd-gen TKIs
CNS surveillance throughout disease course given high metastatic propensity

9. Inheritance and Population

Epidemiology

EGFR mutation prevalence varies dramatically by ethnicity and geography:

Population	EGFR Mutation Prevalence	Source
East Asian	~30%	PMID: 21527061
Caucasian	~7%	PMID: 21527061
Bangladeshi	23%	PMID: 23299280
Moroccan	14.4%	PMID: 33079008
Malaysian (resectable)	62.3%	PMID: 41617518
French	~15%	PMID: 40155080
Egyptian	20.4%	PMID: 41327362

"Compared with Caucasian patients with NSCLC, East Asian patients have a much higher prevalence of epidermal growth factor receptor (EGFR) mutation (approximately 30% vs. 7%, predominantly among patients with adenocarcinoma and never-smokers)" (PMID: 21527061).

Genetic Etiology Characteristics

Inheritance: Somatic (not inherited); germline susceptibility variants modify risk
Penetrance: Not applicable for somatic driver; germline risk alleles have incomplete penetrance (OR 1.19–1.36)
Founder effects: BIM deletion polymorphism enriched in East Asian populations (~12–18% prevalence vs. <1% in Europeans)

Population Demographics

Sex ratio: Female predominance (~60–70% of EGFR-mutant cases)
Age distribution: Peak incidence 55–70 years; young patients (<50) have higher frequency of actionable drivers including EGFR, ALK, ROS1, and ERBB2 (PMID: 41793321)
Geographic distribution: Highest prevalence in East Asia (Japan, China, South Korea, Taiwan); intermediate in South/Southeast Asia; lowest in Northern Europe and North America
Never-smoker relevance: "Asian never smokers have a 2.3-fold higher baseline incidence of lung cancer than non-Asian never smokers, and Asian female never smokers exhibit lung cancer detection rates comparable to Asian male ever smokers" (PMID: 41932615)

10. Diagnostics

Molecular Testing (Standard of Care)

Comprehensive molecular profiling is mandatory for all non-squamous NSCLC at diagnosis:

Test	Application	Sensitivity	Key Findings
NGS panel (tissue)	Gold standard	>95%	Covers exons 18-21; detects co-mutations
PCR-based assays (tissue)	Targeted EGFR testing	~95%	Rapid turnaround
Liquid biopsy (ctDNA)	Tissue unavailable; monitoring	68-88%	Concordance 82.9% with tissue (PMID: 35343188)
Pleural effusion cfDNA	Enhanced detection with MPE	88%	Superior to tissue in some settings (PMID: 39799785)

Liquid biopsy concordance: "The concordance between plasma and tissue testing was found to be 82.9% (95% confidence interval [CI]: 77.55, 87.45). The sensitivity and specificity of NGS were 68.4% and 90.1%, respectively" (PMID: 35343188).

Imaging Studies

CT chest with contrast: Primary staging
PET-CT: Systemic staging
Brain MRI: Mandatory at diagnosis and during surveillance
LDCT: Screening (currently limited to smokers; gap for never-smokers)

Biomarkers

Predictive: EGFR mutation status (TKI response), T790M (osimertinib response), BIM deletion (reduced TKI response), C797S (4th-gen TKI candidates)
Prognostic: TP53 co-mutation (adverse), PD-L1 expression (paradoxically adverse in EGFR-mutant), ctDNA clearance (favorable)
MRD detection: ctDNA-based systems achieving LOD of 0.01% allele fraction (PMID: 35308511)

Histopathology

Predominantly adenocarcinoma (>85%); rarely squamous or adenosquamous
Immunohistochemistry: TTF-1+, CK7+, Napsin A+
PD-L1 IHC assessed but paradoxical prognostic significance in EGFR-mutant tumors

Differential Diagnosis

KRAS-mutant NSCLC (smoking-associated)
ALK-rearranged NSCLC (younger never-smokers)
ROS1-rearranged NSCLC
HER2-mutant NSCLC (newly targetable with zongertinib; PMID: 41985129)
BRAF-mutant NSCLC
Metastatic adenocarcinoma from other primary sites

11. Outcome / Prognosis

Survival

Setting	Treatment	Median PFS	Median OS	Source
Stage IB-IIIA (resected)	Surgery alone	—	5-yr OS 81%	PMID: 41353641
Stage IB-IIIA (resected)	Surgery + adj. osimertinib	Significantly improved DFS	Significant OS benefit	ADAURA
Stage III (unresectable)	CRT + osimertinib	NR vs 3.7 mo (HR 0.16)	Immature	PMID: 41785639
Stage IV (1L)	Osimertinib	~18.9 months	~38.6 months	FLAURA
Stage IV (1L)	Afatinib	~11.0 months	28.8 months	PMID: 41223879
Stage IV (1L)	Gefitinib	—	25.3 months	PMID: 41223879
Stage IV (sequential)	Afatinib → osimertinib	—	55 months	PMID: 41862776
Post-TKI (2L+)	Sacituzumab tirumotecan	HR 0.49 vs chemo	HR 0.60 vs chemo	PMID: 41520595

Prognostic Factors

Favorable: Exon 19 deletion (vs L858R), younger age, good PS (ECOG 0-1), absence of CNS metastases, ctDNA clearance, smaller PTV (<450 cc for stage III)
Adverse: TP53 co-mutation, high PD-L1 (≥50%), BIM deletion polymorphism, positive pleural lavage cytology (HR 2.13 for RFS; PMID: 41145016), smoking history (for ILD risk)

Complications

Brain metastases (25–40%); leptomeningeal metastases (3–5%)
Malignant pleural effusion
Treatment-related ILD (3.7% TKI-induced)
Skeletal-related events from bone metastases
Treatment-related dermatologic, GI, and hepatic toxicities

12. Treatment

Treatment Algorithm

{{figure:treatment_algorithm.png|caption=Treatment algorithm for EGFR-mutant NSCLC across disease stages showing standard of care and emerging combination strategies}}

First-Line Metastatic Treatment

Standard of care: Osimertinib (MAXO:0000058 — pharmacotherapy)

"Osimertinib demonstrates superior efficacy across multiple endpoints in patients with EGFR-mutant" NSCLC — meta-analysis of 16 studies (4,931 patients): ORR RR = 1.59 (95% CI 1.16–2.17) (PMID: 41907704).

Emerging first-line combinations:

Regimen	Trial	Key Efficacy	Toxicity Consideration
Osimertinib + platinum-pemetrexed	FLAURA2	Improved PFS	Higher hematologic toxicity
Amivantamab + lazertinib	MARIPOSA	PFS and OS benefit	Cutaneous, edema, infusion reactions
EGFR TKI + bevacizumab	BIM-CLICaP	Particularly beneficial in BIM-del patients	Anti-VEGF AEs

"EGFR-TKIs plus Bev conferred a significantly higher ORR and PFS in advanced NSCLC patients with EGFR mutation and BIMdel" (PMID: 34994616).

Perioperative Treatment

Adjuvant osimertinib (ADAURA) is the reference standard: "adjuvant osimertinib now representing the most mature perioperative strategy because it has demonstrated durable disease-free survival, overall survival, and central nervous system (CNS) benefit in ADAURA" (PMID: 42033967).

Unresectable Stage III

CRT + consolidation osimertinib (LAURA): In the China cohort, "median BICR-assessed PFS was not reached (17.4–not calculable) versus 3.7 months (1.8–7.7) with osimertinib versus placebo" (PMID: 41785639).

CNS-Directed Therapy

{{figure:plot_5.png|caption=CNS metastasis management algorithm and the critical screening gap for never-smokers with EGFR mutations showing osimertinib CNS response rates and unscreened high-risk populations}}

"Osimertinib penetrates the blood-brain barrier and achieves greater exposure in the brain compared with other EGFR-TKIs" (PMID: 36652172). Meta-analysis: "the overall response rate (ORR) and disease control rate (DCR) were 70% and 92%, respectively, in patients with T790M mutations" with CNS metastases; ORR 71% and DCR 93% in untreated advanced EGFR+ NSCLC with CNS metastases; median PFS 12.21 months (PMID: 32954743).

Post-Resistance Strategies

Agent/Regimen	Mechanism	Key Data
Sacituzumab tirumotecan	TROP-2 ADC	HR 0.49 (PFS), HR 0.60 (OS) vs chemo; "significantly improved OS over chemo-immunotherapy (HR 0.68)" (PMID: 41520595)
Amivantamab + chemotherapy	EGFR-MET bsAb + chemo	HR 0.48 (PFS) vs chemo
Datopotamab deruxtecan	TROP-2 ADC	Meaningful efficacy; EGFR-mutated subgroup response ratio 1.70 (PMID: 41443486)
Vabametkib + lazertinib	MET TKI + EGFR TKI	Synergistic in MET-amplified PDX models; phase II ongoing (NCT05541822) (PMID: 41927036)
4th-gen TKIs (BDTX-1535, JIN-A02, HS-10504)	Allosteric EGFR inhibitors	Phase I/II for L858R/T790M/C797S (PMID: 40667612)
Ivonescimab	PD-1/VEGFA bispecific	Case reports of benefit in complex resistance (PMID: 41479892)

For C797S-positive patients: "chemotherapy-based therapies demonstrated superior PFS vs non-chemotherapy (5.5 vs 3.4 months, p=0.014)" (PMID: 41430586).

Pharmacogenomics

BIM deletion polymorphism: "BIM deletion polymorphism may confer resistance to EGFR-TKIs and can be used as a biomarker to predict treatment response to EGFR-TKIs in EGFR-mutant NSCLC patients from Asian populations" (PMID: 34722761). Resminostat (HDAC inhibitor) can circumvent BIM-del-associated apoptosis resistance in preclinical models (PMID: 33148913).
Lazertinib: Potentially cardio-safer alternative to osimertinib with "superior selectivity for mutant EGFR while sparing wild-type EGFR" (PMID: 40919674)

13. Prevention

Primary Prevention

Smoking avoidance (although EGFR-mutant NSCLC predominantly affects never-smokers)
Environmental exposure reduction: radon mitigation, air quality improvements, cooking ventilation
Occupational safety regulations

Secondary Prevention (Screening)

Critical unmet need: "never smokers remain excluded from current screening guidelines despite rising incidence and identifiable high-risk subgroups" (PMID: 41932615). Evidence supporting expanded screening: - Family history confers 1.7-fold higher incidence - "Asian never smokers have a 2.3-fold higher baseline incidence of lung cancer than non-Asian never smokers" - "Screening trials in never smokers demonstrated detection rates comparable to smoker-based trials, suggesting certain demographic subgroups may reach risk thresholds where screening could be beneficial"

Tertiary Prevention

Adjuvant osimertinib: Prevents recurrence in resected stage IB-IIIA
Consolidation osimertinib: Prevents progression after CRT for unresectable stage III
ctDNA-based MRD monitoring: Enables early detection of recurrence
Regular brain MRI surveillance: Detects asymptomatic CNS metastases early

14. Other Species / Natural Disease

Comparative Biology

EGFR ortholog (highly conserved): Mouse Egfr (NCBI Gene: 13649); Rat Egfr (NCBI Gene: 24329); Zebrafish egfra (NCBI Gene: 378478); Drosophila Egfr/DER (FlyBase: FBgn0003731)
Spontaneous EGFR-mutant lung tumors are not well documented in companion animals
The EGFR kinase domain is >90% conserved between human and mouse, supporting murine model utility
Canine pulmonary adenocarcinoma shares histological features with human NSCLC but EGFR mutation status is rarely characterized

15. Model Organisms

Mouse Models

Model	Type	Key Features	Limitations
EGFR L858R transgenic	Conditional knock-in	Develops lung adenocarcinoma; TKI-sensitive	Single mutation; no tumor heterogeneity
EGFR exon 19 del	Conditional knock-in	Recapitulates human exon 19 deletion tumors	Limited immune microenvironment modeling
EGFR T790M/L858R	Compound knock-in	Models acquired resistance	Does not fully recapitulate all resistance mechanisms
PDX models	Patient-derived xenograft	Preserves tumor heterogeneity; used for drug testing (e.g., vabametkib + lazertinib PMID: 41927036)	Immunodeficient host

Cell Line Models

Cell Line	EGFR Status	Key Application
PC-9	Exon 19 deletion	TKI sensitivity; BIM-del studies (PMID: 33148913)
HCC827	Exon 19 deletion (amplified)	Resistance modeling; CRISPR screens (PMID: 40414926)
NCI-H1975	L858R/T790M	Third-generation TKI testing
PC-9 BIMi2-/-	Exon 19 del + BIM-del (engineered)	Pharmacogenomic studies

Advanced Model Systems

Patient-derived organoids: Used for drug sensitivity testing
CRISPR functional genomics screens: Identified AP-1/NuRD/PRC2 resistance network (PMID: 40414926)
TraCe-seq: Tracked clonal differential responses to EGFR inhibitors (PMID: 34531539)
3D collagen spheroid models: Evaluated invasive phenotypes in TKI-resistant cells (PMID: 42087187)
Single-cell CTC analysis: Demonstrated inter- and intra-patient heterogeneity in EGFR mutation status and gene expression (PMID: 32700450)

Key Findings Summary

F1: Ethnic Variation in EGFR Mutation Prevalence

EGFR mutation prevalence varies dramatically by ethnicity: approximately 30% in East Asians versus ~7% in Caucasians, with intermediate rates in South Asian (23%) and North African (14.4%) populations (PMID: 21527061; PMID: 23299280).

F2: Osimertinib as Standard First-Line Treatment

Osimertinib demonstrates superior ORR, PFS, and OS versus earlier-generation TKIs. Sequential afatinib → osimertinib achieves median OS of 55 months (PMID: 41907704; PMID: 41862776).

F3: C797S as Primary On-Target Resistance to Osimertinib

C797S is the most common on-target resistance mechanism, with diverse bypass mechanisms. Fourth-generation TKIs are in clinical development (PMID: 37060646; PMID: 41430586).

F4: Paradoxical Immune Microenvironment

High PD-L1 (≥50%) paradoxically predicts shorter PFS (HR 3.03) and OS on osimertinib, representing a biologically distinct phenotype (PMID: 41977474; PMID: 41371099).

F5: Superior CNS Efficacy of Osimertinib

CNS ORR of 70–71% with several-fold higher BBB penetration than other EGFR-TKIs. Adjuvant osimertinib reduces CNS recurrence (PMID: 32954743; PMID: 36652172).

F6: Lineage Plasticity as Resistance Mechanism

Epigenetic reprogramming enables histologic transformation (adenocarcinoma → SCLC). TP53/RB1 co-mutations predispose to this transformation (PMID: 41516316).

F7: Lipid-Associated Macrophages in CNS Resistance

RNASE1+ lipid-associated macrophages regulated by Midkine drive osimertinib resistance and leptomeningeal metastasis via CD47-SIRPA interactions (PMID: 39116206).

F8: ADAURA Adjuvant Standard

Adjuvant osimertinib provides durable DFS, OS, and CNS recurrence benefit for resected stage IB-IIIA EGFR-mutant NSCLC (PMID: 42033967; PMID: 41353641).

F9: TCGA Mutation Distribution Confirmed

L858R (26.7%), exon 19 deletions (23.3%), uncommon sensitizing (11.6%), T790M (2.3%) in TCGA LUAD cohort.

F10: GWAS Susceptibility Loci

Six germline loci identified, with HLA class II (OR 1.36) and FOXP4 (OR 1.19) specifically associated with EGFR mutation-positive tumors (PMID: 27501781).

F11: EGFR TKI Adverse Event Profile

Class-specific toxicities documented across 34 RCTs: dermatologic, GI, hepatic, and respiratory AEs. ILD rare but potentially fatal (PMID: 38824269).

F12: Never-Smoker Genomic Landscape

Distinct mutational signatures (clock-like, APOBEC) with high EGFR mutation prevalence and unique allelic differences by smoking status (PMID: 39052387; PMID: 41617518).

F13: Never-Smoker Screening Gap

Asian never-smokers have 2.3-fold higher incidence; screening trials show comparable detection rates to smoker-based programs, yet never-smokers remain excluded from guidelines (PMID: 41932615).

F14: Germline DNA Repair Gene Contributions

ATM, BRCA1/2, TP53, PALB2, CHEK2 germline mutations contribute to NSCLC susceptibility with prognostic and predictive implications (PMID: 41933854).

F15: Osimertinib CNS Efficacy Quantified

Pooled ORR 70%, DCR 92% in T790M+ CNS metastases; ORR 71%, DCR 93% in untreated CNS metastases; median PFS 12.21 months (PMID: 32954743).

F16: BIM Deletion as Pharmacogenomic Modifier

Present in 15.8% of Asian EGFR-mutant patients; predicts shorter PFS (HR 1.35); bevacizumab addition overcomes resistance (PMID: 34722761; PMID: 34994616).

F17: AP-1 as Targetable Resistance Mediator

CRISPR screen identified FOSL1/JUN (AP-1) as top resistance mediators via epigenetic reprogramming; pharmacological inhibition reinstates sensitivity (PMID: 40414926).

Mechanistic Model

GERMLINE SUSCEPTIBILITY              ENVIRONMENTAL EXPOSURE
(HLA class II, TERT, TP63,          (Radon, air pollution, cooking
 FOXP4, BIM-del polymorphism)         fumes, APOBEC mutagenesis)
   │                                    │
   └──────────────┬─────────────────────┘
          ▼
      SOMATIC EGFR MUTATION
 (Exon 19 del / L858R / others)
          │
          ▼
   CONSTITUTIVE EGFR KINASE ACTIVITY
          │
   ┌──────────────┼──────────────┐
   ▼              ▼              ▼
      RAS-MAPK-ERK   PI3K-AKT-mTOR  JAK-STAT3
   │              │              │
   ▼              ▼              ▼
    Proliferation    Anti-apoptosis  Immune evasion
    Cell survival    Metabolism      Low TMB, cold TME
                    Paradoxical PD-L1
          │
          ▼
      LUNG ADENOCARCINOMA
(Stage I-IV at presentation)
          │
   ┌──────────────┼──────────────┐
   ▼              ▼              ▼
      Local growth   CNS metastasis  Systemic mets
    (25-40%)        (bone, liver,
                     adrenal, pleura)
          │
          ▼
      EGFR TKI TREATMENT
(1st/2nd/3rd generation)
          │
          ▼
      ACQUIRED RESISTANCE
   ┌──────────┬──────────┬──────────┐
   ▼          ▼          ▼          ▼
       On-target   Bypass    Histologic  Epigenetic
       (T790M,     (MET amp, (SCLC      (AP-1/NuRD/
C797S)      fusions)  transform)  PRC2)
   │
   ▼
    NEXT-LINE THERAPY
    (4th-gen TKIs, ADCs, bsAbs,
     MET inhibitors, combinations)

Evidence Base

This report synthesizes 104 publications across multiple evidence types:

Evidence Type	Count	Key Examples
Meta-analyses	~10	TKI efficacy (PMID: 41907704), AE profiles (PMID: 38824269), BIM-del (PMID: 34722761), CNS (PMID: 32954743), post-TKI (PMID: 41520595)
Landmark clinical trials	~8	FLAURA, ADAURA, LAURA, MARIPOSA, PAPILLON, PACIFIC
GWAS	1	Japanese EGFR-mutant LUAD susceptibility (PMID: 27501781)
Single-cell/spatial studies	~5	Lipid-associated macrophages (PMID: 39116206), TraCe-seq (PMID: 34531539), STK24 (PMID: 41168822)
CRISPR screens	1	AP-1 resistance network (PMID: 40414926)
Real-world cohorts	~15	South Korea, Taiwan, Portugal, India, Italy, China, Malaysia, Morocco, Bangladesh, Egypt
Genomic database analyses	~5	TCGA/cBioPortal, KEGG, COSMIC
Liquid biopsy studies	~10	ctDNA concordance, MRD detection, cfDNA monitoring
Review articles	~25	Treatment algorithms, resistance mechanisms, screening

Limitations and Knowledge Gaps

Limited diversity in genomic studies: Most GWAS data from East Asian populations; susceptibility loci in African and Latin American populations remain undefined
Resistance heterogeneity: Post-osimertinib resistance mechanisms are diverse and often co-occurring; comprehensive profiling at resistance is not routinely performed
Immunotherapy optimization: Optimal strategy to overcome the immunologically cold microenvironment remains unclear; clinical trials of ICI + TKI combinations show mixed results with increased toxicity
Never-smoker screening: No large randomized trial has established LDCT screening benefits specifically in never-smoker populations
Biomarker gaps: Predictive biomarkers for choosing between first-line strategies (osimertinib monotherapy vs. FLAURA2 vs. MARIPOSA) are lacking
Treatment sequencing: Optimal post-progression sequencing after front-line combination therapy is undefined
Long-term survivorship: Data on 10-year outcomes with sequential TKI strategies are limited
Epigenetic resistance translation: Clinical development of AP-1 targeting and epigenetic therapies remains at early stages
Rare mutations: Optimal treatment for uncommon EGFR mutations (exon 20 insertions, compound mutations) continues to evolve
Health equity: Access to molecular testing, novel therapies, and clinical trials varies significantly between high- and low-resource settings

Proposed Follow-up Experiments / Actions

High Priority

Never-smoker screening trials: Randomized LDCT screening studies in high-risk never-smoker populations (Asian women, family history positive), incorporating ctDNA and AI-enhanced imaging
Resistance mechanism profiling: Systematic tissue and liquid biopsy at progression on first-line osimertinib-based combinations to define resistance patterns
AP-1 targeting clinical trials: Develop and test AP-1 pharmacological inhibitors in combination with osimertinib for epigenetic resistance
BIM-del prospective validation: Pharmacogenomic trial of BIM deletion-guided therapy selection (standard TKI vs. TKI + bevacizumab vs. TKI + HDAC inhibitor)

Medium Priority

Biomarker-driven treatment selection: Develop composite biomarkers (mutation subtype, co-mutations, ctDNA dynamics, BIM-del) to guide first-line intensity
Microenvironment-directed therapy: Clinical trials targeting MDK/RNASE1+ macrophages combined with osimertinib for CNS disease
Fourth-generation TKI development: Accelerate BDTX-1535 and JIN-A02 clinical trials for C797S-positive patients
Multi-ethnic GWAS: Expand to African, Latin American, and Middle Eastern populations

Lower Priority

Organoid biobanks: Establish diverse PDO biobanks representing all mutation subtypes and resistance mechanisms
Prevention studies: Evaluate radon mitigation and air quality interventions in high-risk never-smoker communities

Ontology Summary

Category	Term	ID
Disease	Non-small cell lung carcinoma	MONDO:0005233
Disease	Lung adenocarcinoma	MONDO:0008903
Gene	EGFR	HGNC:3236
Gene	TP53	HGNC:11998
Gene	BCL2L11 (BIM)	HGNC:994
Phenotype	Neoplasm of the lung	HP:0100526
Phenotype	Cough	HP:0012735
Phenotype	Dyspnea	HP:0002094
Cell type	Type II pneumocyte	CL:0002063
Cell type	Macrophage	CL:0000235
Anatomy	Lung	UBERON:0002048
Anatomy	Brain	UBERON:0000955
Pathway	EGFR signaling	GO:0007173
Pathway	MAPK cascade	GO:0000165
Pathway	PI3K-AKT signaling	KEGG:hsa04151
Process	Cell proliferation	GO:0008283
Process	Apoptotic process	GO:0006915
Process	EMT	GO:0001837
Chemical	Osimertinib	CHEBI:90943
Chemical	Gefitinib	CHEBI:49668
Chemical	Erlotinib	CHEBI:114785
Treatment	Pharmacotherapy	MAXO:0000058
Treatment	Surgical resection	MAXO:0000004
Treatment	Radiation therapy	MAXO:0000015
Treatment	Genetic testing	MAXO:0000127

Report generated from 5 iterations of autonomous investigation, 17 confirmed findings, and 104 reviewed publications. Last updated: 2026-05-06.

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)

1. Disease Information

Overview

Key Identifiers

Synonyms and Alternative Names

Information Sources

2. Etiology

Disease Causal Factors

Risk Factors

Genetic Risk Factors

Environmental Risk Factors

Protective Factors

Gene-Environment Interactions

3. Phenotypes

Clinical Symptoms and Signs

Phenotype Characteristics

Treatment-Related Phenotypes (EGFR-TKI Adverse Events)

4. Genetic/Molecular Information

Causal Gene: EGFR

Pathogenic Variants

Modifier Genes

Epigenetic Information

5. Environmental Information

Environmental Factors

Lifestyle Factors

Infectious Agents

6. Mechanism / Pathophysiology

Molecular Pathways

Cellular Processes

Protein Dysfunction

Resistance Mechanisms

Immune System Involvement

Molecular Profiling

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

Subcellular Level

Localization

8. Temporal Development

Onset

Progression and Staging (AJCC 8th Edition)

Disease Course

Critical Periods

9. Inheritance and Population

Epidemiology

Genetic Etiology Characteristics

Population Demographics

10. Diagnostics

Molecular Testing (Standard of Care)

Imaging Studies

Biomarkers

Histopathology

Differential Diagnosis

11. Outcome / Prognosis

Survival

Prognostic Factors

Complications

12. Treatment

Treatment Algorithm

First-Line Metastatic Treatment

Perioperative Treatment

Unresectable Stage III

CNS-Directed Therapy